REMARKS

This responds to the Office Action dated October 18, 2006, the Advisory Action dated February 5, 2007, and the decision of the Board of Patent Appeals and Interferences dated August 31, 2009.

Claims 32, 33, and 38-42 are currently amended; no claims are currently canceled; and no claims are currently added; as a result, claims 32-42 are pending and subject to examination in this application.

Interview Summary

The Applicant expresses its gratitude to Examiner Najarian for the courtesies extended to the Applicant's representatives Mr. Bradley Forrest and Mr. David D'Zurilla during an in-person interview at the United States Patent Office on October 15, 2009.

The Applicant's representatives discussed with Examiner Najarian the Board decision of August 31, 2009, and in particular the Board's holding that the Lilly reference disclosed an exclusive data storage because in the Board's view the database in Lilly contains all relevant data related to the distribution of a drug and the process of distributing it. The Applicant's representatives discussed with Examiner Najarian the amendment to the claims in response to this holding by the Board. Specifically, the Applicant has amended the claims so that the prescriptions are received only at the central pharmacy and that all prescriptions are processed only by the exclusive pharmacy and using only the exclusive computer database.

The Applicant's representatives discussed with Examiner Najarian a further amendment to the claims in which the computer system determines that the sensitive drug is mailed to patients only if no potential abuse is found. The Applicant's representatives note that no potential abuse is found when no abuse has been found by both the patient and the doctor.

The Applicant's representatives further discussed the extensive approval process that the Applicant and the Food and Drug Administration (FDA) were involved in relating to a new indication for the drug gamma hydroxyl butyrate (GHB), and how the patent application was borne out of this FDA approval process.

Examiner Najarian expressed her concerns that the Ukens reference disclosed a single pharmacy, that the claims did not specifically recite that the computer system executed the steps of the claimed method, that the claims did not identify the potential abuse, and that the Lilly reference discloses in paragraph [0054] multi-source interstate prescriptive medication abuse.

No agreement on the claims or the claim amendments was reached.

§103 Rejection of the Claims

Claims 32, 38 and 42 were rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Moradi et al. (U.S. Patent Publication No. 2004/0019794 A1) in view of Lilly et al. (U.S. Patent Publication No. 2004/0176985 A1) in view of Califano et al. (U.S. Patent Publication No. 2003/0033168 A1) and further in view of Ukens ("Specialty Pharmacy").

The Applicant has amended claim 32 to recite the additional features of:

> "receiving in a computer processor all prescription requests, for any and all patients being prescribed the sensitive drug, only at the exclusive central pharmacy from any and all medical doctors allowed to prescribe the sensitive drug . . . ;
>
> requiring entering of the information into an exclusive computer database associated with the exclusive central pharmacy for analysis of potential abuse situations, such that all prescriptions for the sensitive drug are processed only by the exclusive central pharmacy using only the exclusive computer database;
>
> . . . checking with the computer processor the credentials of the any and all doctors;
>
> . . . ~~only~~ mailing the sensitive drug to the patient only if no potential abuse is found by the patient to whom the sensitive drug is prescribed and the doctor prescribing the sensitive drug".

Support for the amendment that recites "receiving in a computer processor all prescription requests, for any and all patients being prescribed the prescription drug, only at the exclusive central pharmacy from any and all medical doctors allowed to prescribe the sensitive drug" can be found in the specification at page 1, lines 27-29.

Support for the amendment that recites ". . . such that all prescriptions for the sensitive drug are processed only by the exclusive central pharmacy using only the exclusive computer database" can be found in the specification at page 1, lines 27-28 and page 4, line 29 – page 5, line 1.

Support for the amendment that recites "mailing the sensitive drug to the patient only if no potential abuse is found by the patient to whom the sensitive drug is prescribed and the doctor prescribing the sensitive drug" can be found in the specification at page 1, lines 27-31.

The Applicant respectfully submits that these amendments differentiate the claimed subject matter over the references of record at least because none of the references of record, either alone or in combination, discloses "that all prescriptions for [a] sensitive drug are processed only by [an] exclusive central pharmacy using only [an] exclusive computer database" and "mailing the sensitive drug to the patient only if no potential abuse is found by the patient to whom the sensitive drug is prescribed and the doctor prescribing the sensitive drug."

The Moradi reference does not disclose these features. While the Moradi reference discloses a central service station that is used in an automated prescription delivery system,[1] Moradi does not disclose that all prescriptions for a sensitive drug, or all prescriptions for any other drug for that matter, are processed ***only*** by the central service station. That is, Moradi does not disclose, teach, or suggest requiring that a drug be distributed only through its disclosed system. Moradi also does not disclose that a drug is mailed to a patient only if no potential abuse is found by both the patient and the doctor.

The Lilly reference does not disclose these features. The Lilly reference discloses a data storage 122, and even states that it relates to a centralized method for tracking and managing prescriptive medication information.[2] However, Lilly does not disclose that all drugs are processed by its system or method using its data storage 122. Rather, as disclosed by Lilly, each user (such as a doctor, hospital, or pharmacy) may maintain its own database, and the data storage 122 can maintain a copy of this data which is used by the system, or the system can obtain the data by accessing a user's database.[3] In other words, Lilly discloses that each user maintains its own database, and while a user can access the data storage 122 to try to find out

[1] Moradi, ¶ [0006].
[2] Lilly, ¶¶ [0050] and [0061].
[3] Lilly, ¶ [0061].

information about a patient, there is no disclosure in Lilly that all prescriptions for a particular drug must use ***only*** the database 122. Rather, a user could simply use its own database, without any concern for abuse or liability, or use its own database and the database 122. In contrast, the claimed subject matter recites that all prescriptions are processed ***only*** by a central pharmacy using ***only*** an exclusive database. Further, Lilly does not disclose that a drug is mailed to a patient only if no potential abuse is found by both the patient and the doctor.

The Califano reference does not disclose these features. The Califano reference relates to managing informed consent processes in clinical trials or medical procedures. The Applicant respectfully submits that it does not disclose a system or method wherein "all prescriptions for [a] sensitive drug are processed only by [an] exclusive central pharmacy using only [an] exclusive computer database" or "mailing the drug to the patients only if no potential abuse is found by the patient to whom the drug is prescribed and the doctor prescribing the sensitive drug" as is recited in claim 32.

The Ukens reference does not disclose the feature that a drug is mailed to a patient only if no potential abuse is found by both the patient and the doctor.

Moreover, even if all the elements of the claimed subject matter were disclosed in the cited references, and the Applicant respectfully reiterates that none of the references, either alone or in combination, discloses "all prescriptions for [a] sensitive drug are processed only by [an] exclusive central pharmacy using only [an] exclusive computer database" and "mailing the sensitive drug to the patients only if no potential abuse is found by the patient to whom the sensitive drug is prescribed and the doctor prescribing the sensitive drug," the Applicant respectfully submits that a *prima facie* case of obviousness still does not exist. The cited references, taken as a whole, simply would not have lead one of skill in the art to come up with the claimed subject matter.

Specifically, the Moradi reference relates to the distribution of a plurality of prescription medicines, and in particular, after validating the prescription and selecting a delivery location based on the location of the patient, the prescribed medicine is delivered to the patient.[4] And while there is a check in Moradi to prevent prescription abuse, the check is only of an individual

[4] Moradi, Abstract.

patient to determine if that patient is permitted to have a prescription filled twice.[5] This is much different than a system in which "all prescriptions for [a] sensitive drug are processed only by [an] exclusive central pharmacy using only [an] exclusive computer database" and wherein the sensitive drug is mailed to the patient only if no potential abuse is found by "the patient to whom the sensitive drug is prescribed and the doctor prescribing the sensitive drug" as is recited in claim 32.

Similarly, the Lilly reference relates to tracking prescriptions only on a per patient basis. Specifically, the Lilly system and method allows a determination of a "complete prescriptive medication history of ***the*** patient"[6] by "obtaining a medication history of ***a selected prescription medication purchaser*** for all prescriptive medicines purchased by ***the selected prescriptive medication purchaser*** from all of the plurality of unaffiliated pharmacies based on the transferred pharmaceutical computer data."[7] So, like in Moradi, Lilly focuses on a single patient. This is much different than a system in which "all prescriptions for [a] sensitive drug are processed only by [an] exclusive central pharmacy using only [an] exclusive computer database" as is recited in claim 32.

The Califano reference does not even relate to tracking prescriptions, either on a per patient or per drug basis. Ukens does not disclose providing a sensitive drug to a patient only if no potential abuse is found by the patient prescribed the sensitive drug and the doctor prescribing the sensitive drug.

In summary, these references simply do not relate to the tracking of a particular sensitive drug using an exclusive central pharmacy and an exclusive central database to determine potential abuse by the doctors who are permitted to prescribe such sensitive drugs and the patients to whom prescriptions are written. Consequently, a *prima facie* case of obviousness does not exist, and the Applicant respectfully requests a withdrawal of the rejection of the claims.

In response to the concerns expressed by Examiner Najarian during the Interview of October 15, 2009, the Applicant offers the following.

---

[5] Moradi, ¶ [0045].
[6] Lilly, Abstract (*Emphasis Added*).
[7] Lilly, ¶ [0037] (*Emphasis Added*).

Examiner Najarian stated that the Ukens reference discloses a single pharmacy. The Applicant respectfully replies that Ukens does not disclose mailing a sensitive, prescriptive, or other drug to a patient only if no potential abuse is found by the patient to whom the drug is prescribed and the doctor prescribing the sensitive drug, as is recited in the claims. The Applicant further respectfully submits that no other reference of record discloses this feature.

Examiner Najarian stated that the claims recited that the computer system was used to perform the steps, not that the computer system performed the steps. The Applicant has amended the claims, and respectfully submits that the amendments address and overcome the concerns of Examiner Najarian.

Examiner Najarian stated that the claim phrase that recites that the drug is mailed only if no potential abuse is found recites patients "or" doctors. The Applicant has amended the claims to recite patients "and" doctors.

Examiner Najarian stated that the claims did not identify the potential abuse. The Applicant respectfully submits that the particular type of abuse is not what the Applicant considers its invention to be, and therefore respectfully submits that the claims should not be limited by any particular type of abuse. The specification provides examples of abuse such as reselling drugs for profit,[8] and the Applicant respectfully submits that one of skill in the art would realize that the claimed subject matter could be applied to other abuse situations.

In response to the Applicant's amendment that the sensitive drug is mailed to a patient only if no potential abuse is found by the patient and the doctor, Examiner Najarian brought to the attention of the Applicant's representatives paragraph [0054] of Lilly that discusses "multi-source interstate prescriptive medication abuse." The Applicant respectfully submits that this is not a disclosure of the claimed feature of mailing a sensitive drug to a patient only if no abuse is found by the patient and the doctor. Indeed, the Applicant respectfully submits that Lilly is directed to obtaining a medication history of a selected prescriptive medication purchaser,[9] and that any multi-source interstate feature of Lilly is only for that selected purchaser, not that selected purchaser ***and*** the doctor prescribing the drug as recited in the claims.

[8] Applicant's specification, page 1, lines 9-21.
[9] Lilly, paragraph [0037].

Independent claims 38 and 42 have been amended in a manner substantially similar to the amendments to claim 32. As indicated above, it is believed that claim 32 is allowable over the cited references, and the Applicant respectfully submits that for substantially similar reasons, claims 38 and 42 are also allowable over the cited references.

Claims 33-36 were rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Moradi et al. (U.S. Patent Publication No. 2004/0019794 A1) in view of Lilly et al. (U.S. Patent Publication No. 2004/0176985 A1).

Claim 37 was rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Moradi et al. (U.S. Patent Publication No. 2004/0019794 A1) in view of Lilly et al. (U.S. Patent Publication No. 2004/0176985 A1) and further in view of Melker et al. (U.S. Patent Publication No. 2002/0177232 A1).

Independent claim 33 has been amended in a manner substantially similar to the amendments to claim 32. As indicated above, it is believed that claim 32 is allowable over the cited references, and the Applicant respectfully submits that for substantially similar reasons, claims 33-37 are also allowable over the cited references.

Claims 39-41 were rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Moradi et al. (U.S. Patent Publication No. 2004/0019794 A1) in view of Lilly et al. (U.S. Patent Publication No. 2004/0176985 A1) in view of Califano et al. (U.S. Patent Publication No. 2003/0033168 A1) and further in view of "Talk About Sleep: An Interview with Orphan Medical about Xyrem".

Independent claims 39, 40, and 41 have been amended in a manner substantially similar to the amendments to claim 32. As indicated above, it is believed that claim 32 is allowable over the cited references, and the Applicant respectfully submits that for substantially similar reasons, claims 39, 40, and 41 are also allowable over the cited references.

CONCLUSION

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612) 371-2140 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

DAYTON T. REARDAN ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2140

Date November 2, 2009

By /David D'Zurilla/
David D'Zurilla
Reg. No. 36,776

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 2 day of November 2009.

John D. Gustav-Wrathall
Name

/John D. Gustav-Wrathall/
Signature

Electronic Patent Application Fee Transmittal	
Application Number:	10322348
Filing Date:	17-Dec-2002
Title of Invention:	Sensitive drug distribution system and method
First Named Inventor/Applicant Name:	Dayton T. Reardan
Filer:	Gregory M. Stark/John Gustav-Wrathall
Attorney Docket Number:	101.031US1
Filed as Small Entity	

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Request for continued examination	2801	1	405	405
		Total in USD ($)		**405**

Electronic Acknowledgement Receipt	
EFS ID:	6377668
Application Number:	10322348
International Application Number:	
Confirmation Number:	5446
Title of Invention:	Sensitive drug distribution system and method
First Named Inventor/Applicant Name:	Dayton T. Reardan
Customer Number:	21186
Filer:	Gregory M. Stark/John Gustav-Wrathall
Filer Authorized By:	Gregory M. Stark
Attorney Docket Number:	101.031US1
Receipt Date:	02-NOV-2009
Filing Date:	17-DEC-2002
Time Stamp:	18:47:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$405
RAM confirmation Number	4650
Deposit Account	190743
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		101031us1_rcef_110209.pdf	403579 3ee1f076760a56f03603cd4bed6f7d79157cb851	yes	20

Multipart Description/PDF files in .zip description

Document Description	Start	End
Request for Continued Examination (RCE)	1	1
Transmittal Letter	2	3
Information Disclosure Statement (IDS) Filed (SB/08)	4	4
Amendment After Final	5	5
Claims	6	12
Applicant Arguments/Remarks Made in an Amendment	13	20

Warnings:					
Information:					
2	NPL Documents	101031US4PAMD04-01-05.pdf	274175 e5889267a31113c39697c3412d7945026019d92a	no	7
Warnings:					
Information:					
3	NPL Documents	101-031US42.pdf	878785 1d8812144d014505680a469fe54dd5a6d17b9d4c	no	22
Warnings:					
Information:					
4	NPL Documents	899009US2_AARN_02-02-05.pdf	859394 1baf1b5eaca7de48e613235ad48efed91f429a0f	no	17
Warnings:					
Information:					
5	NPL Documents	101031US2PAMD11-02-04.pdf	59199 ca16c29ae38c7adfece7253af3bf691680315cf5	no	3

Warnings:					
Information:					
6	NPL Documents	101031US3PAMD04-01-05.pdf	231951 8af010e62dfdc14bcc023852022c703a0512 8fe3	no	6
Warnings:					
Information:					
7	NPL Documents	101031US3-NF.pdf	731364 19e58ba578e5c22b79ead1c02873a08c3e2 74d7a	no	21
Warnings:					
Information:					
8	NPL Documents	101031US3_AARN_09-17-09.pdf	135890 c1c0078430ca62e2c0be1ebe06aed7d0f33 1a6f0	no	10
Warnings:					
Information:					
9	Fee Worksheet (PTO-875)	fee-info.pdf	29941 1d1d042b0ded5ba5c0dab35d69c080941f 31aff8	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	3604278		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (07-06)
Approved for use through 1/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 10/322,348	Filing Date 12/17/2002	☐ To be Mailed

APPLICATION AS FILED – PART I

	(Column 1)	(Column 2)	SMALL ENTITY ☒		OR	OTHER THAN SMALL ENTITY	
FOR	NUMBER FILED	NUMBER EXTRA	RATE ($)	FEE ($)		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =		OR	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =			X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	

APPLICATION AS AMENDED – PART II

		(Column 1)		(Column 2)	(Column 3)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
	11/02/2009	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)		RATE ($)	ADDITIONAL FEE ($)
AMENDMENT	Total (37 CFR 1.16(i))	* 20	Minus	** 31	= 0	X $26 =	0	OR	X $ =	
	Independent (37 CFR 1.16(h))	* 7	Minus	***7	= 0	X $110 =	0	OR	X $ =	
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE	0	OR	TOTAL ADD'L FEE	

		(Column 1)		(Column 2)	(Column 3)					
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)		RATE ($)	ADDITIONAL FEE ($)
AMENDMENT	Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =		OR	X $ =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =		OR	X $ =	
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

Legal Instrument Examiner:
/WANDA ANTHONY/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

21186 7590 12/31/2009

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

EXAMINER	
NAJARIAN, LENA	
ART UNIT	PAPER NUMBER
3686	

DATE MAILED: 12/31/2009

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/322,348	12/17/2002	Dayton T. Reardan	101.031US1	5446

TITLE OF INVENTION: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	$755	$300	$0	$1055	03/31/2010

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

21186 7590 12/31/2009

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)

(Signature)

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/322,348	12/17/2002	Dayton T. Reardan	101.031US1	5446

TITLE OF INVENTION: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	$755	$300	$0	$1055	03/31/2010

EXAMINER	ART UNIT	CLASS-SUBCLASS
NAJARIAN, LENA	3686	705-002000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:

❑ Issue Fee

❑ Publication Fee (No small entity discount permitted)

❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): (**Please first reapply any previously paid issue fee shown above**)

❑ A check is enclosed.

❑ Payment by credit card. Form PTO-2038 is attached.

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)

❑ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

❑ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/322,348	12/17/2002	Dayton T. Reardan	101.031US1	5446

21186 7590 12/31/2009

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

EXAMINER	
NAJARIAN, LENA	
ART UNIT	PAPER NUMBER
3686	

DATE MAILED: 12/31/2009

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 446 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 446 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

Notice of Allowability	Application No.	Applicant(s)	
	10/322,348	REARDAN ET AL.	
	Examiner	Art Unit	
	LENA NAJARIAN	3686	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *11/2/09*.

2. ☒ The allowed claim(s) is/are *32-42*.

3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
   a) ☐ All b) ☐ Some* c) ☐ None of the:
      1. ☐ Certified copies of the priority documents have been received.
      2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
      3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
      1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
   (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 20091102
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

DETAILED ACTION

Examiner's Amendment

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with David D'Zurilla (Reg. No. 36,776) on 12/10/09.

The application has been amended as follows:

32. (Currently Amended) A computerized method of distributing a ~~sensitive~~ prescription drug under exclusive control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor all prescription requests, for any and all patients being prescribed the ~~sensitive~~ prescription drug, only at the exclusive central pharmacy from any and all medical doctors allowed to prescribe the ~~sensitive~~ prescription drug, the prescription requests containing information identifying patients, the ~~sensitive~~ prescription drug, and various credentials of the any and all medical doctors;

requiring entering of the information into an exclusive computer database associated with the exclusive central pharmacy for analysis of potential abuse situations, such that all prescriptions for the ~~sensitive~~ prescription drug are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all doctors to determine the eligibility of the doctors to prescribe the prescription drug;

confirming with a patient that educational material has been read prior to shipping the ~~sensitive~~ prescription drug;

checking the exclusive computer database for potential abuse of the ~~sensitive~~ prescription drug;

mailing the ~~sensitive~~ prescription drug to the patient only if no potential abuse is found by the patient to whom the ~~sensitive~~ prescription drug is prescribed and the doctor prescribing the ~~sensitive~~ prescription drug;

confirming receipt by the patient of the ~~sensitive~~ prescription drug; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential diversion patterns.

33. (Currently Amended) A computerized method of distributing a ~~sensitive~~ prescription drug under exclusive control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor all prescription requests, for any and all patients being prescribed the ~~sensitive~~ prescription drug, only at the exclusive central pharmacy from any and all medical doctors allowed to prescribe the ~~sensitive~~ prescription drug, the prescription requests containing information identifying patients, the ~~sensitive~~ prescription drug, and various credentials of the any and all medical doctors;

entering the information into an exclusive computer database associated with the exclusive central pharmacy for analysis of potential abuse situations, such that all prescriptions for the ~~sensitive~~ prescription drug are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all doctors to determine the eligibility of the doctors to prescribe the prescription drug;

checking the exclusive computer database for potential abuse of the ~~sensitive~~ prescription drug;

mailing the ~~sensitive~~ prescription drug to a patient only if no potential abuse is found by the patient to whom the ~~sensitive~~ prescription drug is prescribed and the doctor prescribing the ~~sensitive~~ prescription drug;

confirming receipt by the patient of the ~~sensitive~~ prescription drug; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential diversion patterns.

35. (Currently Amended) The method of claim 33 and further comprising selectively blocking shipment of the ~~sensitive~~ prescription drug to a patient.

37. (Currently Amended) The method of claim 33 wherein the ~~sensitive~~ prescription drug comprises gamma hydroxy butyrate (GHB).

38. (Currently Amended) A computerized method of distributing a ~~sensitive~~ prescription drug under control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor prescription requests, for any and all patients being prescribed the ~~sensitive~~ prescription drug, only at the central pharmacy from any and all authorized prescribers allowed to prescribed the ~~sensitive~~ prescription drug, the prescription requests containing information identifying patients, the ~~sensitive~~ prescription drug, and various credentials of the any and all authorized prescribers;

entering the information into an exclusive computer database under exclusive control of the central pharmacy for analysis of potential abuse situations, wherein the use of the exclusive computer database is required for distribution of the ~~sensitive~~

prescription drug, such that all prescriptions for the ~~sensitive~~ prescription drug are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all authorized prescribers to determine the eligibility of the prescribers to prescribe the prescription drug;

confirming with a patient that educational material has been read prior to providing the ~~sensitive~~ prescription drug to the patient;

requiring checking of the exclusive computer database for potential abuse associated with the patient and the authorized prescriber;

providing the ~~sensitive~~ prescription drug to the patient only provided information in the exclusive computer database is not indicative of potential abuse by the patient to whom the ~~sensitive~~ prescription drug is prescribed and the authorized prescriber of the ~~sensitive~~ prescription drug;

confirming receipt by the patient of the ~~sensitive~~ prescription drug; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential diversion patterns.

39. (Currently Amended) A computerized method of distributing gamma hydroxy butyrate (GHB) under control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor prescription requests for GHB, for any and all patients being prescribed GHB, only at the central pharmacy from any and all authorized prescribers allowed to prescribe GHB, the prescription requests for GHB containing information identifying patients and various credentials of the any and all authorized prescribers;

entering the information into an exclusive computer database under exclusive control of the central pharmacy for analysis of potential abuse situations, wherein the use of the exclusive computer database is required for distribution of GHB, such that all

prescriptions for GHB are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all authorized prescribers to determine the eligibility of the prescribers to prescribe GHB;

confirming with the patient that GHB educational material has been read prior to providing GHB to the patient a first time;

requiring checking of the exclusive computer database for potential GHB abuse associated with the patient;

providing GHB to the patient only provided information in the exclusive computer database is not indicative of potential abuse by the patient to whom GHB is prescribed and the authorized prescriber of the GHB;

confirming receipt by the patient of the GHB; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential GHB diversion patterns.

40. (Currently Amended) A computerized method of distributing gamma hydroxy butyrate (GHB) under control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor prescription requests for GHB, for any and all patients being prescribed GHB, only at the central pharmacy from any and all authorized prescribers allowed to prescribe GHB, the prescription requests containing information identifying patients and various credentials of the any and all authorized prescribers;

entering the information into an exclusive computer database under exclusive control of the central pharmacy for analysis of potential abuse situations, wherein the use of the exclusive computer database is required for distribution of GHB, such that all prescriptions for ~~the sensitive drug~~ GHB are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all authorized prescribers to determine the eligibility of the prescribers to prescribe GHB;

confirming with the patient that GHB educational material has been read prior to providing GHB to the patient a first time;

requiring checking of the exclusive computer database for potential GHB abuse associated with the patient;

mailing GHB to the patient only provided information in the exclusive computer database is not indicative of potential abuse by the patient to whom GHB is prescribed and the authorized prescriber of the GHB;

confirming receipt by the patient of the GHB; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential GHB diversion patterns.

41. (Currently Amended) A computerized method of distributing gamma hydroxy butyrate (GHB) under control of an exclusive central pharmacy, the method comprising:

manufacturing GHB;

providing manufactured GHB only to the exclusive central pharmacy;

receiving in a computer processor all prescription requests for GHB, for any and all patients being prescribed GHB, only at the central pharmacy from any and all authorized prescribers allowed to prescribe GHB, the prescription requests containing information identifying patients and various credentials of the any and all authorized prescribers;

entering the information into an exclusive computer database under exclusive control of the central pharmacy for analysis of potential abuse situations, wherein the use of the exclusive computer database is required for distribution of GHB, such that all prescriptions for GHB are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all authorized prescribers to determine the eligibility of the prescribers to prescribe GHB;

confirming with the patient that GHB educational material has been read prior to providing GHB to the patient a first time;

requiring checking of the exclusive computer database for potential GHB abuse associated with the patient;

mailing GHB to the patient only provided information in the exclusive computer database is not indicative of potential abuse by the patient to whom GHB is prescribed and the doctor prescribing the GHB;

confirming receipt by the patient of the GHB; and

generating with the computer processor periodic reports via the exclusive computer database to evaluate potential GHB diversion patterns.

42. (Currently Amended) A computerized method of distributing a ~~sensitive~~ prescription drug under control of an exclusive central pharmacy, the method comprising:

receiving in a computer processor all prescription requests, for any and all patients being prescribed the ~~sensitive~~ prescription drug, only at the central pharmacy from any and all authorized prescribers allowed to prescribed the ~~sensitive~~ prescription drug, the prescription requests containing information identifying patients, the ~~sensitive~~ prescription drug, and various credentials of the any and all authorized prescribers;

entering the information into an exclusive computer database under exclusive control of the central pharmacy for analysis of potential abuse situations, wherein the use of the exclusive computer database is required for distribution of the ~~sensitive~~ prescription drug, such that all prescriptions for the ~~sensitive~~ prescription drug are processed only by the exclusive central pharmacy using only the exclusive computer database;

checking with the computer processor the credentials of the any and all authorized prescribers to determine the eligibility of the prescribers to prescribe the prescription drug;

confirming with the patient that educational material has been read prior to providing the ~~sensitive~~ prescription drug to the patient;

requiring checking of the exclusive computer database for potential abuse by the patient to whom the ~~sensitive~~ prescription drug is prescribed and the authorized prescriber allowed to prescribe the ~~sensitive~~ prescription drug;

providing the ~~sensitive~~ prescription drug to the patient only provided information in the exclusive computer database is not indicative of potential abuse by the patient to whom the ~~sensitive~~ prescription drug is prescribed and the authorized prescriber allowed to prescribe the ~~sensitive~~ prescription drug; and

confirming receipt by the patient of the ~~sensitive~~ prescription drug.

Allowable Subject Matter

2. Claims 32-42 are allowed.

3. The following is an examiner's statement of reasons for allowance: Claims 32, 33, 38, and 42, now renumbered as claims 1, 2, 7, and 11, are directed to a computerized method of distributing a prescription drug under exclusive control of an exclusive central pharmacy.

The closest prior art of record, Moradi (US 2004/0019794 A1), Lilly et al. (US 2004/0176985 A1), Califano et al. (US 20030033168 A1), and Ukens ("Specialty Pharmacy") teach receiving prescription requests, checking the credentials of the doctors, checking a database for potential abuse of the drug, confirming receipt by the patient of the drug, confirming with the patient that educational material has been read prior to shipping the drug, generating reports to evaluate potential diversion patterns, and restricting distribution of a medication to one pharmacy.

However, the closest prior art of record does not teach or fairly suggest that *all* prescriptions for the prescription drug are processed only by the exclusive central pharmacy *using only the exclusive computer database.* The exclusive computer database is checked for potential abuse of the prescription drug and the prescription drug is mailed/provided only if no potential abuse is found by the patient to whom the prescription drug is prescribed *and* the doctor/authorized presciber prescribing the prescription drug.

Dependent claims 34-37 (now renumbered as claims 3-6) incorporate the allowable subject matter of claim 33, through dependency, and are also allowable for the same reasons.

Claims 39, 40, and 41 are directed to a computerized method of distributing gamma hydroxy butyrate (GHB) under control of an exclusive central pharmacy.

The closest prior art of record, Moradi (US 2004/0019794 A1), Lilly et al. (US 2004/0176985 A1), Califano et al. (US 20030033168 A1), and Talk About Sleep ("An Interview with Orphan Medical about Xyrem") teach receiving prescription requests, checking the credentials of the doctors, checking a database for potential abuse of the drug, confirming receipt by the patient of the drug, confirming with the patient that educational material has been read prior to shipping the drug, generating reports to evaluate potential diversion patterns, and providing GHB through a specialty distribution system that utilizes a central pharmacy.

However, the closest prior art of record does not teach or fairly suggest that *all* prescriptions for GHB are processed only by the exclusive central pharmacy *using only the exclusive computer database.* The exclusive computer database is checked for potential GHB abuse and GHB is provided/mailed only if no potential abuse is found by the patient to whom GHB is prescribed *and* the doctor/authorized prescriber of the GHB.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

4. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LENA NAJARIAN whose telephone number is (571) 272-7072. The examiner can normally be reached on Monday - Friday, 9:30 am - 6:00 pm.

6. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jerry O'Connor can be reached on (571) 272-6787. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or (571) 272-1000.

/L. N./
Examiner, Art Unit 3686
ln
12/16/09

/Gerald J. O'Connor/
Supervisory Patent Examiner
Group Art Unit 3686

Notice of References Cited	Application/Control No. 10/322,348	Applicant(s)/Patent Under Reexamination REARDAN ET AL.	
	Examiner LENA NAJARIAN	Art Unit 3686	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-5,737,539	04-1998	Edelson et al.	705/3
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

PTO/SB/08A(04-07)
Modified form approved for use through 09/30/2007. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use as many sheets as necessary)	*Complete if Known*	
	Application Number	10/322,348
	Filing Date	December 17, 2002
	First Named Inventor	Dayton T. Reardan
	Group Art Unit	3686
	Examiner Name	Lena Najarian
Sheet 1 of 1	Attorney Docket No: 101.031US1	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-20020032581A1	03/14/2002	Reitberg, D P	06/01/2001
	US-4,976,351	12/11/1990	Mangini, R. J, et al.	06/01/1989
	US-6,564,121	05/13/2003	Wallace, R. L, et al.	12/03/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T [1]

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [1]
	"Aplication Serial No. 11/097,985 (Atty Ref 101.031US4), Preliminary Amendment mailed 04-01-05", 7 pgs	
	"Application Serial No 11/097,985 Non Final Office Action Mailed 09/14/2009", 22	
	"Application Serial No. 10/731,915 (Atty Ref 101.031US1), Non Final Office Action Response mailed 02-02-05", 17 pgs	
	"Application Serial No. 10/979,665 (Atty Ref 101.031US2), Preliminary Amendment mailed 11-02-04", 3 pgs	
	"Application Serial No. 11/097,651 (Atty Ref 101.031US3), Preliminary Amendment mailed 04-01-05", 6 pgs	
	"Application Serial No. 11/097,651, Non-Final Office Action mailed 05-29-09", 21 pgs	
	"Application Serial No. 11/097,651, Response filed 09-17-09 to Non Final Office Action mailed 05-29-09", 10 pgs	

EXAMINER	/Lena Najarian/	DATE CONSIDERED	12/16/2009

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.N./

STIC Scientific and Technical Information Center

Search Report
EIC 3600

STIC Database Tracking Number: 317266

To: Lena Najarian **Location: KNX 5A59** **Art Unit: 3686** **Date: 12/15/09** **Case Serial Number:10/322348**	**From:Eileen Patton** **Location: EIC3600** **KNX 2D08A** **Phone: (571) 272-3413** **eileen.patton@uspto.gov**

Search Notes

Dear Examiner Najarian:

Please find attached the results of your search for the above-referenced case. The search was conducted in Dialog, ProQuest, EBSCOhost and the internet.

I have listed *potential* references of interest in the first part of the search results. However, please be sure to scan through the entire report. There may be additional references that you might find useful.

If you have any questions about the search, or need a refocus, please do not hesitate to contact me.

Thank you for using the EIC, and we look forward to your next search!

**EIC-Searcher identified "potential references of interest" are selected based upon their apparent relevance to the terms/concepts provided in the examiner's search request.*

I. Potential References of Interest

A. Dialog

21/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73: EMBASE

0074963062 **EMBASE No:** 1992114735
Policy and medical-legal issues in the prescribing of controlled substances
Clark H.W.
Journal of Psychoactive Drugs (J. PSYCHOACT. DRUGS) (United States) December 1, 1991 , 23/4 (321-328)
CODEN: JPDRD **ISSN:** 0279-1072
Document Type: Journal ; Article **Record Type:** Abstract
Language: English **Summary language:** English
Policy and medical-legal issues in the prescribing of controlled substances
The physician who **prescribes controlled substances** is faced with an array of laws, regulatory policies, and professional attitudes about their use. **Prescriptions** for these scheduled **drugs** are furthermore **monitored** by the pharmacists who dispense them. Certain drugs, such as the opioids and the benzodiazepines, are considered so potentially abusive that special programs have been... ...to track the behavior of physician prescribers. Multiple copy programs have been implemented in some states. More recent proposals recommend electronic data transfer (EDT) of **pharmacy** information to **centralized processing points** so that **misprescribing physicians and doctor- shopping patients can be identified**. Regulators concerned about physician behavior and confronted by demands of nonphysicians to **prescribe controlled substances** may find EDT a good solution. Physicians should be concerned about being censured for misprescribing, because such actions may lead to inclusion in the National Practitioner Data Bank. With all of the regulatory concerns about controlled substances, those physicians who would employ long-term opioid therapy for their chronic pain patients must follow certain basic guidelines to be able to defend themselves against allegations of deviant professional behavior. Such procedures as conducting a history and physical examination, maintaining a written treatment plan, consulting with knowledgeable colleagues, and assessing for addictive behavior can provide the practitioner with safeguards....

22/3,K/4 (Item 4 from file: 636)
DIALOG(R)File 636: Gale Group Newsletter DB(TM)

01055345 **Supplier Number:** 40582007 **(USE FORMAT 7 FOR FULLTEXT)**
LINKS
Health Daily , v 1 , n 108 , p N/A
Nov 23 , 1988
Language: English **Record Type:** Fulltext
Document Type: Magazine/Journal ; Trade
Word Count: 962
-
...cover.

Derville explained that the drug processors or some other entity will have to implement automated drug prepayment and postpayment utilization review of claims to **identify misuse** of drugs. Reviews will address the beneficiary's use of covered drugs, drug interactions and therapies and **physician** prescribing **patterns**. Beneficiary utilization reviews will **identify** potential **abuse** of drugs, such as unusual therapy for age or gender or multiple **prescriptions** for **controlled substances**, while **physician prescribing pattern** reviews will target excessive prescriptions, especially for restrictive drugs, and fragmented patterns of prescribing maintenance-type drugs. Utilization reviews are the "area we know the...

15/3,K/5 (Item 5 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0012649646 *Drawing available*
WPI Acc no: 2002-499029/**200253**
XRAM Acc no: C2002-141338
XRPX Acc No: N2002-395040
Controlled articles distribution tracking method for sample distribution and inventory control, involves confirming authority of sales representative to distribute samples and practitioners to receive samples
Patent Assignee: CHESTER M (CHES-I); DATA REDUCTION SYSTEMS CORP (DATA-N); DEPALMA M J (DEPA-I); MCQUADE R (MCQU-I)
Inventor: CHESTER M; DEPALMA M J; MCQUADE R

Patent Family (2 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20020042762	A1	20020411	US 2000230764	P	20000907	200253	B
			US 2001942803	A	20010830		
US 6952681	B2	20051004	US 2001942803	A	20010830	200565	E

Priority Applications (no., kind, date): US 2000230764 P 20000907; US 2001942803 A 20010830
Original Titles:Tracking the distribution of **prescription drugs** and other **controlled** articles... ...**Tracking** the distribution of **prescription drugs** and other **controlled** articles **Alerting Abstract** ...USE - For real time and automatic **tracking** of distribution of **prescription drug** samples and other **controlled** articles for sample distribution and inventory control... Original Publication Data by AuthorityArgentina**Publication No.** ...**Claims:**comprising a representative identifier, a distributee identifier, and a statement describing the contents of the packet of articles being distributed from the portion of the **central inventory** conveyed to the distributing representative;b) confirming the authority of the distributing representative to distribute the packet;c) confirming the authority of the distributee to... Basic Derwent Week: **200253**

15/3K/10 (Item 6 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00521070

METHOD, SYSTEM AND APPARATUS FOR BIOMETRIC IDENTIFICATION
PROCEDE, SYSTEME ET APPAREIL D'IDENTIFICATION BIOMETRIQUE
Patent Applicant/Patent Assignee:

- **BEECHAM James E**

Inventor(s):

- **BEECHAM James E**

	Country	Number	Kind	Date
Patent	WO	9952422	A1	19991021
Application	WO	99US8120		19990414
Priorities	US	9881891		19980415

...the
autofocus iris scanner of LG Technologies of Korea. The iris scan measurement is encoded and filed in a computerized database optionally within a single **database** of a **central computer**. The **prescribing** physician when **prescribing** a **controlled substance** for a patient will have in his office an iris scanner and will instruct the patient to enter iris data, typically from the right eye, into the scanner. This scanner is linked to the **central database**. The patient encoded iris scan data and the physician encoded iris scan data are thus linked in a data file which optionally includes further specifications... ...When a match
of encoded iris data occurs,, the data is displayed to the pharmacist. In the circumstance where a patient has recently filled another **controlled substance prescription** in the same region, the data of the prior prescription is displayed, and alerts the pharmacist that the **patient** may have a controlled substance **abuse** problem.

In another embodiment of the instant invention the computer at the physician office is a stand alone computer linked to a two dimensional bar...prescription and avoids name mix-ups or pseudonym. The data retrieved may alert authorities such as the state Board of Pharmacy to a problem in **patient** substance **abuse**.

Similarly the database search criteria may be set to identify all physicians who prescribe more than a set number of **controlled substance prescriptions** within a 12-month period. The data retrieved may alert authorities such as the state Board of Pharmacy to a problem with a physician prescribing...is monitored for indication that a person is picking up. medication from multiple pharmacies and for multiple individuals as

might indicate a pattern of substance **abuse** in the case of fraudulent **controlled substance prescriptions**.

It is envisioned that the step of a physician ordering a medication prescription in the instant invention can be a surrogate carrying out the order...circumstance verify via telephone input of physician biometric to the pharmacy computer the fact that physician 412 has decided to authorize a refill of the **prescription** of the **controlled substance** for patient 414. Alternatively where the match of patient 414 biometric data in the database includes information the pharmacist interprets as a pattern of controlled substance **abuse** the **pharmacist** may decline to fill the prescription or alternatively alert **physician** 412 to the possible **abuse** of controlled substance medication by **patient** 414.

Turning now to Fig. 6, illustrated is a patient 601 in a hospital bed who has previously received a prescription order from his physician...

II. Inventor Search Results from Dialog

9/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)

0020219855 **Biosis No.:** 200800266794
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Author: Anonymous; Cook Harry; Hamilton Martha; Danielson Douglas; Goderstad Colette; **Reardan Dayton**
Author Address: Eden Prairie, MN USA**USA
Journal: Official Gazette of the United States Patent and Trademark Office Patents AUG 28 2007 2007
Patent Number: US 07262219 **Patent Date Granted:** August 28, 2007 20070828 **Patent Classification:** 514-557 **Patent Assignee:** Orphan Medical Inc **Patent Country:** USA
ISSN: 0098-1133
Document Type: Patent
Record Type: Abstract
Language: English
Author: ...**Reardan Dayton**

9/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)

18017375 **Biosis No.:** 200400388164
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Author: Cook Harry (Reprint); Hamilton Martha; Danielson Douglas; Goderstad Colette ; **Reardan Dayton**
Author Address: Eden Prairie, MN, USA**USA
Journal: Official Gazette of the United States Patent and Trademark Office Patents 1285 (4): Aug. 24, 2004 2004
Medium: e-file
Patent Number: US 6780889 **Patent Date Granted:** August 24, 2004 20040824 **Patent Classification:** 514-557 **Patent Assignee:** Orphan Medical, Inc., Minnetonka, MN, USA **Patent Country:** USA
ISSN: 0098-1133 _(ISSN print)
Document Type: Patent
Record Type: Abstract
Language: English
Author: ...**Reardan Dayton**

9/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73: EMBASE

0079522002 **EMBASE No:** 2003228233
Effects of estradiol, phytoestrogens, and Ginkgo biloba extracts against 1-methyl-4-phenyl-pyridine-induced oxidative stress
Gagne B.; Gelinas S.; Bureau G.; Lagace B.; Ramassamy C.; Chiasson K.; Valastro B.; Martinoli M.-G.
Department of Biochemistry, Research Group in Neuroscience, Univ. du Que. a Trois-Rivieres, Trois-Rivieres, Que., Canada
Author email: martinol@uqtr.uquebec.ca

Corresp. Author/Affil: Martinoli M.-G.: Department of Biochemistry, Universite du Quebec, C.P. 500, Trois-Rivieres, Que. G9A 5H7, Canada
Corresp. Author Email: martinol@uqtr.uquebec.ca
Endocrine (Endocrine) (United States) June 1, 2003 , 21/1 (89-95)
CODEN: EOCRE **ISSN:** 0969-711X
Item Identifier (DOI): 10.1385/ENDO:21:1:89
Document Type: Journal ; Article **Record Type:** Abstract
Language: English **Summary language:** English
Number of References: 56
Gagne B...

26/3,K/1 (Item 1 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015351683 *Drawing available*
WPI Acc no: 2005-701943/200572
Related WPI Acc No: 2004-516067; 2005-354186; 2005-701214
XRPX Acc No: N2005-576014
Food and drug administration approval acquisition method of e.g. narcotics, involves selecting controls from group containing identifying physician name and license, and verifying whether physician is eligible to prescribe drug
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: ENGEL P A; **GAGNE B**; **REARDAN D T**

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20050222874	A1	20051006	US 2002322348	A	20021217	200572	B
			US 200597651	A	20050401		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 200597651 A 20050401

...Inventor: **GAGNE B**... ...**REARDAN D T** Original Publication Data by AuthorityArgentina**Publication No.**
Inventor name & address:**Reardan, Dayton T**... ...**Gagne, Bob**

26/3,K/2 (Item 2 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015350954 *Drawing available*
WPI Acc no: 2005-701214/200572
Related WPI Acc No: 2004-516067; 2005-354186; 2005-701943
XRPX Acc No: N2005-575389
Abuse control method of sensitive drug e.g. cocaine, involves providing database for drug enforcement agency for checking abuse patterns of drug, with respect to each cash payment and inappropriate questions
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: ENGEL P A; **GAGNE B**; **REARDAN D T**

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type

US 20050216309	A1	20050929	US 2002322348	A	20021217	200572	B
			US 200597985	A	20050401		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 200597985 A 20050401
...Inventor: **GAGNE B**... ...**REARDAN D T** Original Publication Data by AuthorityArgentina**Publication No.** Inventor name & address:**Reardan, Dayton T**... ...**Gagne, Bob**

26/3,K/3 (Item 3 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015006281 *Drawing available*
WPI Acc no: 2005-354186/200536
Related WPI Acc No: 2004-516067; 2005-701214; 2005-701943
XRPX Acc No: N2005-289217
Sensitive drug e.g. Xyrem, distributing method for treating cataplexy, involves making periodic reports via database to evaluate potential abuse patterns, where database has information identifying patient, drug and credentials
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: **ENEEL P A**; **GAGNE B**; **REARDAN D T**

Patent Family (1 patents, 1 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20050090425	A1	20050428	US 2002322348	A	20021217	200536	B
			US 2004979665	A	20041102		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 2004979665 A 20041102
Inventor: **ENEEL P A**... ...**GAGNE B**... ...**REARDAN D T** Original Publication Data by AuthorityArgentina**Publication No.** Inventor name & address:**Reardan, Dayton T**... ...**Eneel, Patti A**... ...**Gagne, Bob**

26/3,K/4 (Item 4 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0014328324 *Drawing available*
WPI Acc no: 2004-516067/200449
Related WPI Acc No: 2005-354186; 2005-701214; 2005-701943
XRPX Acc No: N2004-408813
Sensitive drug e.g. cocaine, distributing method, involves confirming with patient that educational material has been read prior to shipping, confirming receipt of drug, and generating periodic reports via central database
Patent Assignee: ENEEL P A (ENEE-I); GAGNE B (GAGN-I); REARDAN D T (REAR-I)
Inventor: **ENEEL P A**; **GAGNE B**; **REARDAN D T**

Patent Family (1 patents, 1 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20040117205	A1	20040617	US 2002322348	A	20021217	200449	B

Priority Applications (no., kind, date): US 2002322348 A 20021217

Inventor: **ENEEL P A**... ...**GAGNE B**... ...**REARDAN D T** Original Publication Data by AuthorityArgentina**Publication No.** Inventor name & address:**Reardan, Dayton T**... ...**Eneel, Patti A**... ...**Gagne, Bob**

26/3,K/5 (Item 5 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0012745923
WPI Acc no: 2002-598783/200264
Related WPI Acc No: 2000-465620
XRAM Acc no: C2002-168978
Stable composition of gamma-hydroxybutryate in aqueous medium, rendered chemically stable and resistant to microbial growth, useful for treating e.g. sleep disorders
Patent Assignee: COOK H N (COOK-I); DANIELSON D (DANI-I); GODERSTAD C (GODE-I); HAMILTON M (HAMI-I); REARDAN D (REAR-I)
Inventor: COOK H N; DANIELSON D; GODERSTAD C; HAMILTON M; **REARDAN D**

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20020077334	A1	20020620	US 1999470570	A	19991222	200264	B

Priority Applications (no., kind, date): US 1999470570 A 19991222
...Inventor: **REARDAN D** Original Publication Data by AuthorityArgentina**Publication No.** ...Inventor name & address:**REARDAN, DAYTON**

26/3,K/6 (Item 6 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0010395368
WPI Acc no: 2000-465620/200040
Related WPI Acc No: 2002-598783
XRAM Acc no: C2000-140186
Aqueous compositions of gamma-hydroxybutyric acid are chemically stable and resistant to microbial growth and include a pH adjusting agent and a preservative
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: COOK H; COOK H N; DANIELSON D; GODERSTAD C; HAMILTON M; **REARDAN D**; **REARDAN D T**; DOUGLAS D

Patent Family (20 patents, 87 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2000038672	A2	20000706	WO 1999US30740	A	19991222	200040	B
AU 200020590	A	20000731	AU 200020590	A	19991222	200050	E
EP 1140061	A2	20011010	EP 1999964320	A	19991222	200167	E
			WO 1999US30740	A	19991222		
US 6472431	B2	20021029	US 1998113745	P	19981223	200274	E
			US 1999470570	A	19991222		

JP 2002533388	W	20021008	WO 1999US30740	A	19991222	200281	E
			JP 2000590626	A	19991222		
EP 1140061	B1	20030502	EP 1999964320	A	19991222	200330	E
			WO 1999US30740	A	19991222		
			EP 200375658	A	19991222		
EP 1316309	A1	20030604	EP 1999964320	A	19991222	200337	E
			EP 200375658	A	19991222		
DE 69907508	E	20030605	DE 69907508	A	19991222	200345	E
			EP 1999964320	A	19991222		
			WO 1999US30740	A	19991222		
US 20030125385	A1	20030703	US 1998113745	P	19981223	200345	E
			US 1999470570	A	19991222		
			US 2002194021	A	20020711		
ES 2193777	T3	20031101	EP 1999964320	A	19991222	200382	E
US 6780889	B2	20040824	US 1998113745	P	19981223	200457	E
			US 1999470570	A	19991222		
			US 2002194021	A	20020711		
US 20040209955	A1	20041021	US 1998113745	P	19981223	200470	E
			US 1999470570	A	19991222		
			US 2002194021	A	20020711		
			US 2004841709	A	20040507		
AU 779354	B2	20050120	AU 200020590	A	19991222	200512	E
CA 2355293	C	20050816	CA 2355293	A	19991222	200557	E
			WO 1999US30740	A	19991222		
IL 143733	A	20061031	IL 143733	A	19991222	200680	E
US 7262219	B2	20070828	US 1998113745	P	19981223	200757	E
			US 1999470570	A	19991222		
			US 2002194021	A	20020711		
			US 2004841709	A	20040507		
US 20070270491	A1	20071122	US 1998113745	P	19981223	200779	E
			US 1999470570	A	19991222		
			US 2002194021	A	20020711		
			US 2004841709	A	20040507		
			US 2007777877	A	20070713		
IN 200702633	P2	20080801	WO 1999US30740	A	19991222	200929	E
			IN 2001KN688	A	20010629		
			IN 2007KN2633	A	20070713		

JP 2009167189	A	20090730	JP 2000590626	A	19991222	200950	E
			JP 200928694	A	20090210		
IN 225248	B	20081107	WO 1999US30740	A	19991222	200967	E
			IN 2001KN688	A	20010629		
			IN 2007KN2633	A	20070713		

Priority Applications (no., kind, date): US 1998113745 P 19981223; US 1999470570 A 19991222; US 2002194021 A 20020711; US 2004841709 A 20040507; US 2007777877 A 20070713
...Inventor: **REARDAN D**... ...**REARDAN D T** Original Publication Data by AuthorityArgentina**Publication No.**
...Inventor name & address:**REARDAN D**... ...**REARDAN D**... ...**REARDAN, Dayton**... ...**REARDAN, Dayton**... ...**Reardan, Dayton T**... ...**REARDAN D T**... ...**Reardan, Dayton**... ...**Reardan, Dayton**... ...**Reardan, Dayton**... ...**Reardan, Dayton**... ...**Reardan, Dayton**... ...**Reardan, Dayton**... ...**REARDAN, Dayton**

DIALOG(R)File 348: EUROPEAN PATENTS

31/3K/1 (Item 1 from file: 348)
01589939
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Mikrobenbestandige und stabilisierte Losungen die gamma-Hydroxybuttersauresalze zur Behandlung von Narkolepsie enthalten
Solutions de sels d'hydroxybutyrate stables et saines au plan microbiologique,pour le traitement de la narcolepsie
Patent Assignee:

- **Orphan Medical Inc.** (2715280)
  Suite 475, 13911 Ridgedale Drive; Minnetonka, MN 55305 (US)
  (Applicant designated States: all)

Inventor:

- **Goderstad, Colette**
  469 Hills Courte North; St. Paul, Minnesota 55113; (US)
- **Hamilton, Martha**
  306 South Exchange Street; St. Paul, Minnesota 55102; (US)
- **Cook, Harry N.**
  15441 Village Woods Drive; Eden Prairie, Minnesota 55437; (US)
- **Reardan, Dayton T.**
  22345 Bracketts Road; Excelsior, Minnesota 55331; (US)
- **Danielson, Douglas**
  1594 Wood Lea Drive; Otsego, Michigan 49078-9755; (US)
- **...US)**
  ; ;
- **Reardan, Dayton T...**
  ; ;

Legal Representative:

- **Lucas, Brian Ronald (33295)**
  Lucas & Co. 135 Westhall Road; Warlingham, Surrey CR6 9HJ; (GB)

	Country	Number	Kind	Date	
Patent	EP	1316309	A1	20030604	(Basic)
Application	EP	2003075658		19991222	
Priorities	US	113745	P	19981223	

31/3K/3 (Item 1 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00890823
GAMMA-HYDROXYBUTYRATE COMPOSITIONS CONTAINING CARBOHYDRATE, LIPID OR AMINO ACID CARRIERS
COMPOSITIONS DE GAMMA-HYDROXYBUTYRATE CONTENANT DES EXCIPIENTS GLUCIDES, LIPIDES, OU ACIDES AMINES
Patent Applicant/Patent Assignee:

- **ORPHAN MEDICAL INC**
  Suite 475, 13911 Ridgedale Drive, Minnetonka, MN 55305; US; US(Residence); US(Nationality); (For all designated states except: US)

Patent Applicant/Inventor:

- **MILLER Brian L**
  21508 Maple Avenue, Rogers, MN 55374; US; US(Residence); US(Nationality)
- **MAMELAK Mortimer**
  19 Tumbleweed Road, Toronto, M2J 2N2; CA; CA(Residence); CA(Nationality); (Designated only for: US)
- **HOUGHTON William C**
  1034 Summit Avenue, St. Paul, MN 55105; US; US(Residence); US(Nationality); (Designated only for: US)
- **REARDAN Dayton T**
  22345 Bracketts Road, Excelsior, MN 55331; US; US(Residence); US(Nationality); (Designated only for: US)
- **...Designated only for: US)**
- **REARDAN Dayton T...**

Legal Representative:

- **VIKSNINS Ann S (agent)**
  Schwegman, Lunberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402; US

	Country	Number	Kind	Date
Patent	WO	200224715	A2-A3	20020328
Application	WO	2001US29569		20010921
Priorities	US	2000234720		20000922

III. Text Search Results from Dialog

A. Patent Files, Abstract

```
  File 347:JAPIO Dec 1976-2009/May(Updated 090903)
         (c) 2009 JPO & JAPIO
  File 350:Derwent WPIX 1963-2009/UD=200956
         (c) 2009 Thomson Reuters

Set     Items   Description
S1      29177   ((SENSITIVE OR DANGEROUS OR MONITORED OR REGULATED OR RISKY
             OR CONTROLLED OR ADDICTIVE OR MOOD()ALTERING OR ILLEGAL OR H-
             ARD OR (HABIT OR ADDICTION)(1N)FORMING OR NARCOTI?ING OR HAZA-
             RDOUS)(3N)(PHARMACEUTIC? OR PHARMAECEUTIC? OR PHARMACO? OR PH-
             ARMAECO? OR DRUG OR DRUGS OR SUBSTANCE OR SUBSTANCES OR MEDIC-
             ATION? ? OR MEDICINE? ? OR PILLS OR MEDICAMENT? ? OR ANAESTHE-
             TIC OR PAINKILLER? ? OR PAIN()KILLER? ? OR STIMULANT? ?) OR N-
             ARCOTIC? ? OR OPIATE OR OPIATES OR OPIOID? ? OR BENZODIAZEPIN-
             ES OR HYDROCODONE)
S2         99   S1(4N)(PRESCRIPTION? ? OR PRESCRIBE? ? OR PRESCRIBING OR W-
             RITTEN()(ORDER? ? OR INSTRUCTION? ? OR DIRECTION? ?) OR REQUE-
             ST? ? OR SCRIPT? ?)
S3         44   S2(5N)(TRACK? OR MONITOR? OR CONTROL? OR RESTRICT? OR SURV-
             EIL? OR MANAG? OR REGULAT? OR ENFORC? OR INHIBIT? OR LIMIT? OR
              RESTRAIN? OR CONSTRAIN? OR PROHIBIT? OR SUPERVIS? OR CHECKIN-
             G)
S4        159   (ABUSE? ? OR ABUSIVE? OR ABUSING OR ILLEGAL? OR MISUSE OR -
             MIS()(USE OR USED OR USING) OR MISUSED OR MISUSING OR UNSCRUP-
             ULOUS?? OR UNETHICAL OR DRUG()(DEALER? ? OR DEALING) OR DISCI-
             PLINARY()ACTION? ? OR  MALTREATMENT? ? OR IMPROPER?? OR DISRE-
             PUTABLE OR MISTREATMENT? ? OR MISPRESCRIBING)(4N)(IDENTIF? OR
             MONITOR? OR ANALY?E? ? OR ANALYSIS OR ANALY?ING OR WARN? ? OR
             WARNING? ? OR RED()FLAG OR ALERT? OR DETECT? OR REVEAL? OR DI-
             SCOVER? OR EXPOSE? ? OR EXPOSING OR UNCOVER? OR RECOGNI?E? ? -
             OR RECOGNI?ING OR RECOGNITION)
S5        161   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
             ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
             EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
             ACKGROUND? ?)(3N)(PATIENT? ? OR OUTPATIENT? ? OR INPATIENT? ?
             OR REQUESTER? ? OR PRESCRIPTION()HOLDER? ? OR CONSUMER? ? OR -
             INDIVIDUAL? ? OR PERSON? ? OR CLIENT? ? OR PATRON? ? OR CUSTO-
             MER? ? OR BENEFICIARY? ? OR BENEFICIARIES)
S6         16   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
             ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
             EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
             ACKGROUND? ? OR PRECENDENT? ? OR CREDENTIAL? ?)(3N)(PHARMACIS-
             T? ? OR PHARMAECIST? ? OR PHARMACOLOGIST? ? OR PHARMAECOLOGIS-
             T? ? OR DRUGGIST? ? OR CHEMIST? ? OR APOTHECAR? OR PHARMACOPO-
             LIST? ? OR  PHYSICIAN? ? OR DOCTOR? ? OR  CLINICIAN? ? OR SUR-
             GEON? ? OR PROVID?R? ? OR PRACTITIONER? ? OR PROFESSIONAL? ? -
             OR SPECIALIST? ?)
S7        157   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
             OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR SOLO OR RESTRIC-
             TED)(3N)(PHARMACY OR PHARMACIES OR FACILITY OR FACILITIES OR -
             DRUGGIST? ? OR CHEMIST? ? OR STATION? ? OR BUILDING? ? OR LOC-
             ATION? ? OR CENTER? ? OR CENTRE? ? OR CLINIC? ? OR HOSPITAL? ?
              OR OFFICE OR OFFICES OR ESTABLISHMENT? ? OR SITE OR HEAD()QU-
             ARTER? ? OR HEADQUARTER? ? OR HQ OR APOTHECAR? OR DRUGSTORE OR
              STORE)
S8        129   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
             OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR MAINFRAME)(3N)(-
             DATABASE OR DATABASES OR DATABANK? ? OR DATAFILE? ?  OR DATA(-
```

```
             )(BASE OR BASES OR BANK OR BANKS) OR REPOSITOR? OR DB OR D()B
             OR DBMS OR RDBMS OR D()B()M()S OR PORTAL OR PORTALS OR COMPUT-
             ER? ? OR CPU OR SERVER OR SERVERS OR PROCESSOR? ?)
S9          5   S3 AND S4
S10         8   S3 AND (S5 OR S6)
S11         6   S3 AND (S7 OR S8)
S12        10   S9 OR S10 OR S11
S13         3   S12 AND PY=1963:2002
S14         7   S12 AND AY=1963:2002 AND AC=US
S15         7   S13 OR S14
S16         5   S2 AND S4 AND (S5 OR S6)
S17         8   S1 AND S4 AND (S5 OR S6)
S18         4   S17 AND (S7 OR S8)
S19         4   (S16 OR S17 OR S18) NOT S15
S20        11   S2 AND (S5 OR S6)
S21         4   S20 AND (S7 OR S8)
S22         4   (S20 OR S21) NOT (S15 OR S19)
S23         4   S4 AND S5 AND S6
S24         4   S4 AND S7 AND S8
S25         0   (S23 OR S24) NOT (S15 OR S19 OR S22)
S26         6   AU=((REARDAN, D? OR REARDAN D? OR REARDAN(2N)D?) OR (ENEEL,
              P? OR ENEEL P? OR ENEEL(2N)P?) OR (GAGNE, B? OR GAGNE B? OR -
             GAGNE(2N)B?))
```

15/3,K/1 (Item 1 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015351683 *Drawing available*
WPI Acc no: 2005-701943/200572
Related WPI Acc No: 2004-516067; 2005-354186; 2005-701214
XRPX Acc No: N2005-576014
Food and drug administration approval acquisition method of e.g. narcotics, involves selecting controls from group containing identifying physician name and license, and verifying whether physician is eligible to prescribe drug
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: ENGEL P A; GAGNE B; REARDAN D T ***Inventor's Publication***

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20050222874	A1	20051006	US 2002322348	A	20021217	200572	B
			US 200597651	A	20050401		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 200597651 A 20050401
Alerting Abstract ...ADVANTAGE - **Abuses** of drug are **identified**, and education is provided to both physician and patient... Original Publication Data by AuthorityArgentina**Publication No. Original Abstracts:**A drug distribution system and method utilizes a **central** pharmacy and **database to track** all **prescriptions** for **a sensitive drug**. Information is **kept in** the database regarding all physicians allowed to **prescribe** the sensitive **drug**, **and** all **patients receiving** the drug. Abuses are **identified** by **monitoring** data **in** the **database** for prescription **patterns** by physicians and **prescriptions** obtained **by patients**. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken... Basic Derwent Week: 200572

15/3,K/2 (Item 2 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015350954 *Drawing available*
WPI Acc no: 2005-701214/200572
Related WPI Acc No: 2004-516067; 2005-354186; 2005-701943
XRPX Acc No: N2005-575389
Abuse control method of sensitive drug e.g. cocaine, involves providing database for drug enforcement agency for checking abuse patterns of drug, with respect to each cash payment and inappropriate questions
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: ENGEL P A; GAGNE B; REARDAN D T ***Inventor's Publication***

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20050216309	A1	20050929	US 2002322348	A	20021217	200572	B
			US 200597985	A	20050401		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 200597985 A 20050401
Alerting Abstract ...potential prescription abuse of sensitive drug are determined from periodic reports generated by database, based on prescription request data with information identifying patient, prescribed drug, **credential** of **doctor**. The database is made available for drug enforcement agency (DEA) for checking abuse patterns of drug, with respect to cash payment and inappropriate questions. Original Publication Data by AuthorityArgentina**Publication No. Original Abstracts:**A drug distribution system and method utilizes a **central** pharmacy and **database to track** all **prescriptions** for **a sensitive drug**. Information is **kept in** the database regarding all physicians allowed to **prescribe** the sensitive **drug**, **and** all **patients receiving** the drug. Abuses are **identified** by **monitoring** data **in** the **database** for prescription **patterns** by physicians and **prescriptions** obtained **by patients**. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken... Basic Derwent Week: 200572

15/3,K/3 (Item 3 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015006281 *Drawing available*
WPI Acc no: 2005-354186/200536
Related WPI Acc No: 2004-516067; 2005-701214; 2005-701943
XRPX Acc No: N2005-289217
Sensitive drug e.g. Xyrem, distributing method for treating cataplexy, involves making periodic reports via database to evaluate potential abuse patterns, where database has information identifying patient, drug and credentials
Patent Assignee: ORPHAN MEDICAL INC (ORPH-N)
Inventor: ENEEL P A; GAGNE B; REARDAN D T ***Inventor's Publication***

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20050090425	A1	20050428	US 2002322348	A	20021217	200536	B
			US 2004979665	A	20041102		

Priority Applications (no., kind, date): US 2002322348 A 20021217; US 2004979665 A 20041102
Alerting Abstract ...NOVELTY - The method involves entering information identifying a patient, sensitive drug and various **credentials** of a **doctor** into a database to **analyze** potential **abuse** situations, and checking the credentials. A confirmation is made with the patient that educational material has been read prior to shipping the drug. The receipt ... ... a method of **monitoring** potential **abuse** of **a** sensitive **drug** by use of an **exclusive central database** a **method of obtaining** Food and Drug Administration approval for a sensitive drug a therapeutic

method for treating a narcoleptic patient in need of treatment with gamma hydroxy butyrate... ... support via ongoing contact with patients and a toll free helpline. The method maintains and monitors the patient and prescribing physician registries to ensure proper **distribution** of the **sensitive drug**.Original Publication Data by AuthorityArgentina**Publication No. Original Abstracts:**A drug distribution system and method utilizes a **central** pharmacy and **database to track** all **prescriptions** for **a sensitive drug**. Information is **kept in** the database regarding all physicians allowed to **prescribe** the sensitive **drug**, **and** all **patients receiving** the drug. Abuses are **identified** by **monitoring** data **in** the **database** for prescription **patterns** by physicians and **prescriptions** obtained **by patients**. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken... ...**Claims:**of distributing a sensitive drug, the method comprising:receiving prescription requests from a medical doctor containing information identifying the patient, the sensitive drug, and various **credentials** of the doctor;entering the **information** into a **central database** for **analysis** of potential **abuse** situations;**checking the credentials of** the **doctor**;**confirming** with the patient that educational **material** has been **read** prior to shipping the sensitive drug;confirming receipt of the sensitive drug; andgenerating periodic reports via the **central database** to evaluate potential abuse patterns.Basic Derwent Week: 200536

15/3,K/4 (Item 4 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0014328324 *Drawing available*
WPI Acc no: 2004-516067/200449
Related WPI Acc No: 2005-354186; 2005-701214; 2005-701943
XRPX Acc No: N2004-408813
Sensitive drug e.g. cocaine, distributing method, involves confirming with patient that educational material has been read prior to shipping, confirming receipt of drug, and generating periodic reports via central database
Patent Assignee: ENEEL P A (ENEE-I); GAGNE B (GAGN-I); REARDAN D T (REAR-I)
Inventor: ENEEL P A; GAGNE B; REARDAN D T ***Inventor's Publication***

Patent Family (1 patents, 1 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20040117205	A1	20040617	US 2002322348	A	20021217	200449	B

Priority Applications (no., kind, date): US 2002322348 A 20021217
.cocaine, distributing method, involves confirming with patient that educational material has been read prior to shipping, confirming receipt of drug, and generating periodic reports via central database Alerting Abstract ...NOVELTY - The method involves receiving prescription requests from a doctor and entering information into a **central database** for **analysis** of potential **abuse** situations. **Credentials** of the **doctor** are checked and the patient is queried to confirm that educational material has been read prior to shipping. The receipt of the drug is confirmed... DESCRIPTION - The **central database** contains all relevant data related to the distribution of the drug and process of distribution, including patient, physician and prescription information... ... a method of **monitoring** potential **abuse** of **a** sensitive **drug** by use of an **exclusive central database** a **method of obtaining** food and drug administration (FDA) approval for a sensitive drug... ... ADVANTAGE - The **central database** ensures that all prescriptions, prescribers, and patients are **tracked and** subject to investigations, thereby minimizing risk and ensuring that the drugs are not abused. The method provides an education and limits a potential for the abuse. Several queries and reports are run against the database **to** provide information which **reveal** potential **abuse** of the sensitive drug.Original Publication Data by AuthorityArgentina**Publication No. Original Abstracts:**A drug distribution system and method utilizes a **central** pharmacy and **database to track** all **prescriptions** for **a sensitive drug**. Information is **kept in** the database regarding all physicians allowed to **prescribe** the sensitive **drug**, **and** all **patients receiving** the drug. Abuses are **identified** by **monitoring** data **in** the **database** for prescription **patterns** by physicians and **prescriptions** obtained **by patients**. Further verification

is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken... ...**Claims:**of distributing a sensitive drug, the method comprising:receiving prescription requests from a medical doctor containing information identifying the patient, the sensitive drug, and various **credentials** of the doctor;entering the **information** into a **central database** for **analysis** of potential **abuse** situations;**checking the credentials of** the **doctor**;**confirming** with the patient that educational **material** has been **read** prior to shipping the sensitive drug;confirming receipt of the sensitive drug; andgenerating periodic reports via the **central database** to evaluate potential abuse patterns.Basic Derwent Week: 200449

15/3,K/6 (Item 6 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0012649557 *Drawing available*
WPI Acc no: 2002-498938/**200253**
Related WPI Acc No: 2005-675101
XRAM Acc no: C2002-141317
XRPX Acc No: N2002-394958
Pharmaceutical parenteral mixture-compounder comprises computer containing memory for storing process operation and control instructions
Patent Assignee: BAXTER INT INC (BAXT); CZARNY R W (CZAR-I); KIRCHER J J (KIRC-I); LEWIS R E (LEWI-I); MILLER J E (MILL-I); NITZKI-GEORGE D M (NITZ-I)
Inventor: CZARNY R W; KIRCHER J J; LEWIS R E; MILLER J A; MILLER J E; NITZKI-GEORGE D M

Patent Family (2 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20020035412	A1	20020321	US 1999168695	P	19991203	200253	B
			US 2000729498	A	20001204		
US 6975924	B2	20051213	US 2000729498	A	20001204	200581	E

Priority Applications (no., kind, date): US 1999168695 P 19991203; US 2000729498 A 20001204
Technology Focus ...prescription mixtures in the queue to group together the mixtures which have such commonality of predetermined components. The computer also retrieves data relating to a **patient profile**, such as, **patient**'s name, age and weight, or retrieves data relating to categories of patients, such as, adult, pediatric, neo-natal or premature patients. The computer compares... ...a patient in a category and provides a signal when a component is outside of the predetermined limits for the component in the mixture. The **patient**'s **profile** data further includes a **history** of the **patient**'s weight and mixture prescriptions over a period of time. The processing device is provided to prepare a **report** concerning the **patient**, including a projection of the patient's weight at some time in the future. The memory device includes data relating to the amount of fluid... **Extension Abstract** Original Publication Data by AuthorityArgentina**Publication No.** ...**Claims:**least one communication port for establishing a communication link with each compounder that is to be controlled;said computing means being adapted to receive a **prescription** admixture, identify the **pharmaceutical** components thereof, determine the compatibility of the pharmaceutical components relative to one another, determine the order in which the components are transferred in preparing the... Basic Derwent Week: **200253**

19/3,K/1 (Item 1 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0016082131 *Drawing available*
WPI Acc no: 2006-613762/200663 ***Bad Date***
XRAM Acc no: C2006-189501
New isotopically labeled diazepine derivative useful for preventing or stopping prescription drug abuse
Patent Assignee: DR PHARMA NOVA LLC (DRPH-N); REIS A J (REIS-I); SCHAFMEISTER C (SCHA-I)
Inventor: REIS A J; SCHAFMEISTER C

Patent Family (3 patents, 111 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2006091885	A2	20060831	WO 2006US6730	A	20060223	200663	B
CA 2614223	A1	20060831	CA 2614223	A	20060223	200882	E
			WO 2006US6730	A	20060223		
			CA 2614223	A	20080103		
US 20090208413	A1	20090820	US 2005656232	P	20050224	200955	E
			WO 2006US6730	A	20060223		
			US 2008922794	A	20080905		

Priority Applications (no., kind, date): US 2005656232 P 20050224; US 2005656232 P 20050224; US 2008922794 A 20080905

Alerting Abstract ... composition comprising a mixture of a drug having different labels in a specified ratio and a carrier; a method (M1) of preventing or stopping drug **abuse**; a method (M2) of **monitoring** patient compliance with a **prescription** for a **controlled pharmaceutical** agent; a method (M3) of monitoring patient compliance with a prescription for a drug enforcement agency (DEA) schedule II - V drug; a method (M4) of facilitating replacement drug prescription by a provider; a method (M5) of safely tapering a drug; a method (M6) of **prescribing** a labeled **controlled drug** to a patient; and a method (M7) of identifying a non-compliant patient who does not comply with a prescription for medication. R 5 , R... ... USE - For preventing or stopping prescription drug **abuse**, and for **monitoring** patient compliance with a **prescription** for a **controlled pharmaceutical** agent (claimed...

19/3,K/2 (Item 2 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0014443481 *Drawing available*
WPI Acc no: 2004-634162/200461 ***Bad Date***
XRPX Acc No: N2004-501320
Prescription dispensing system for identifying medication abuse, has electronic database associated with computer unit to search database by data item and to perform preset data processing on records to produce data packet
Patent Assignee: ERICSSON A D (ERIC-I); HALL T E (HALL-I)
Inventor: ERICSSON A D; HALL T E

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20040162740	A1	20040819	US 2003367411	A	20030214	200461	B

Priority Applications (no., kind, date): US 2003367411 A 20030214
Prescription dispensing system for identifying medication abuse, has electronic database associated with computer unit to search database by data item and to perform preset data processing on records to

produce data packet Alerting Abstract ... a method for transmitting transaction records to the prescription system from remote sources for addition to the electronic database a method for obtaining a **patient**`s medication **history** a method **for** determining whether **a** proposed transaction will violate prescription fill limitations for a medicinal substance a method for determining whether prescription activity in a given geographic area is indicative... ... 24 Federal **controlled substance** act classification database Original Publication Data by AuthorityArgentina**Publication No.** ...**Original Abstracts:**operably associated with the computer means for communicating the processed data packet to a user. The database can be used to identify prescription fraud, medication **overuse** and **abuse**, and to provide **an** early **warning** for bioterror attacks

19/3,K/4 (Item 4 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0009500628 *Drawing available*
WPI Acc no: 1999-443146/199937
Related WPI Acc No: 1999-346451; 1999-394209; 2000-246158; 2000-524447
XRAM Acc no: C1999-130543
XRPX Acc No: N1999-330421
On-site assaying system for detecting use of illegal drugs etc.
Patent Assignee: ESCREEN INC (ESCR-N); NAT MEDICAL REVIEW OFFICE INC (NAME-N)
Inventor: LAPPE M

Patent Family (2 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 5929422	A	19990727	US 1997832957	A	19970404	199937	B
US RE38509	E	20040504	US 1997832957	A	19970404	200430	E
			US 2001916905	A	20010726		

Priority Applications (no., kind, date): US 1997832957 A 19970404; US 2001916905 A 20010726
On-site assaying system for detecting use of illegal drugs etc. Alerting Abstract ...USE - Assaying system for **detecting** use of **illegal drugs** etc... Original Publication Data by AuthorityArgentina**Publication No.** ...**Claims:**substances within human physiological fluid, at least one fixed strip and at least one blank region also located upon the test card, organized in a **pattern** with the **individual** analysis strips **to** produce an **encoded** machine readable source of data, wherein the analysis strips, upon detecting a proscribed substance, will change from a first color to a second darker color...

22/3,K/1 (Item 1 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0015350955 *Drawing available*
WPI Acc no: 2005-701215/200572
Related WPI Acc No: 2005-701213 ***Bad Date***
XRPX Acc No: N2005-575390
Pharmaceutical inventory computerized monitoring method for inmates in e.g. medication dispensation workstation, involves forming records based on dispensing of unit packet of medication to inmate and consumption of medication by inmate
Patent Assignee: CLEMENTS L M (CLEM-I); HAMMACK G G (HAMM-I); JACKSON K M (JACK-I); MITCHEM S C (MITC-I); UNIV TEXAS SYSTEM (TEXA)
Inventor: CLEMENTS L M; HAMMACK G G; JACKSON K M; MITCHEM S C

Patent Family (2 patents, 107 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20050216310	A1	20050929	US 2004806878	A	20040323	200572	B
WO 2005096209	A2	20051013	WO 2005US9765	A	20050323	200572	E

Priority Applications (no., kind, date): US 2004806878 A 20040323

.**Original Abstracts:**of medicines and pharmaceuticals from a pharmacy and medicinal administration facility for use in correctional facilities, such as in prisons. Information related to past medical **history** of a **patient may** be reviewed **while** simultaneously reviewing a prescription written for the same patient. Prescription filling tasks can also be controlled, such as printing labels for medication in batches to... ... of medicines and pharmaceuticals from a pharmacy and medicinal administration facility for use in correctional facilities, such as in prisons. Information related to past medical **history** of a **patient** may be reviewed (20) while **simultaneously** reviewing a **prescription** written for the same patient. Prescription filling tasks can also be controlled, such as **printing** labels for **medication** in batches **to** assist with the shipment of medication to prison units. Compliance records associated with medicinal administration of prescribed medications to **patients** can also be maintained...

22/3,K/2 (Item 2 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0013669459 *Drawing available*
WPI Acc no: 2003-765859/200372
XRPX Acc No: N2003-613418

Pharmaceuticals interactions analyzing method for patients, involves issuing warning when specified pharmaceutical contains active substance that is incompatible with profile diagnosed information

Patent Assignee: FAGERHOLM M (FAGE-I); KVARNSTROM N (KVAR-I)
Inventor: FAGERHOLM M; KVARNSTROM N

Patent Family (1 patents, 1 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20030144883	A1	20030731	US 2002353495	P	20020130	200372	B
			US 2002283772	A	20021029		

Priority Applications (no., kind, date): US 2002353495 P 20020130; US 2002283772 A 20021029

.**Original Abstracts:**is a computer program for analyzing interactions between pharmaceuticals used by a patient by analyzing the prescribed pharmaceutical with a pharmaceutical profile section showing pharmaceuticals **used** by the **patient**, a diagnose **profile section** showing diagnose **information** about the **patient**, and an over-**sensitivity profile** section showing pharmaceuticals and medical substances to which the patient is sensitive. The program automatically issues warnings if the prescribed drug is incompatible with any... **Claims:** We claim: **1**. A method of analyzing interactions between pharmaceuticals used by a patient, comprising: providing a computer program having patient data information of a **patient**, a pharmaceutical **profile** section showing **pharmaceuticals** used by the **patient**, **a** diagnose **profile section** showing diagnose information about the **patient and** an over-**sensitivity profile** section showing pharmaceuticals and medical substances to which the **patient is** sensitive; analyzing a medical database linked to the computer program to **determine** if a **prescribed pharmaceutical** is incompatible with the diagnose information in the diagnose profile section and issuing a warning when the prescribed pharmaceutical is incompatible with the diagnose information...

22/3,K/3 (Item 3 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0012808978 *Drawing available*
WPI Acc no: 2002-666060/200271
XRPX Acc No: N2002-526997
Handheld printing unified medical prescription transcriber for medical practitioners, retrieves digital data from database by matching digital voice signal with stored data and converts it into transcription format during printing
Patent Assignee: HEGARTY D D (HEGA-I); RODAN ENTERPRISES LLC (RODA-N)
Inventor: HEGARTY D D

Patent Family (2 patents, 1 countries)							
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20020099534	A1	20020725	US 2001770087	A	20010125	200271	B
US 6889190	B2	20050503	US 2001770087	A	20010125	200531	E

Priority Applications (no., kind, date): US 2001770087 A 20010125
.**Original Abstracts:**a unitary hand held medical prescription transcriber and printing unit. More specifically, a small, portable electronic device is provided which can record words spoken by **a physician** and from those words generate a printed medical prescription that is delivered directly from the device itself. The unit digitizes words spoken by the user... ... unitary hand held medical prescription transcriber and printing unit. More specifically, a small, portable electronic device is provided which can record words spoken by a **physician** and from those **words** generate a printed medical prescription that is delivered directly from the device itself. The unit digitizes words spoken by the user, processes the speech to... ... may display the prescription on a liquid crystal display screen and the user may edit the prescription before printing a hard copy. The unit assists **in** accurate dispensing of **medicines** by providing a legible **prescription** printout, while at the same time being neither time consuming nor difficult to operate.

22/3,K/4 (Item 4 from file: 350)
DIALOG(R)File 350: Derwent WPIX

0012283770
WPI Acc no: 2002-224672/200228
Related WPI Acc No: 2002-507329; 2004-106525; 2004-592623; 2005-581344; 2006-779010
Delivering drug, particularly teratogenic or other hazardous drug to patient involves generating prescription approval code to be retrieved by pharmacy before prescription is filled
Patent Assignee: CELGENE CORP (CGEN)
Inventor: KAMINSHI J K; KAMINSKI J K; WILLIAMS B A; KAMINSKI J; WILLIAMS B

MX 2002006176	A1	20020701	WO 2001US29303	A	20001024	200377	E
Patent Number	**Kind**	**Date**	**Application Number**	**Kind**	**Date**	**Update**	**Type**
US 20040126617	A1	20040422	WO 2000US29303	A	20001024	200428	B
WO 2002035440	A1	20020502	WO 2001US29303	A	20001024	200236	E
AU 200114372	A	20020506	AU 200114372	A	20001024	200238	E
BR 0015075	A1	20030318	BR 2001015075	A	20001024	200309	NCE
JP 2006209801	A	20060810	WO 2001US29303	A	20001024	200654	E
EP 1330765	A1	20030730	EP 2001978627	A	20001024	200350	E
NZ 541736	A	20061222	WO 2001US29303	A	20001024	200703	E
CN 1425167	A	20030618	CN 2001818530	A	20001024	200358	E

AU 2005201675	B2	20080313	AU 2005201675	A	20050421	200857	NCE
EP 1970827	A1	20080917	EP 2000976627	A	20001024	200862	E
			EP 200810221	A	20001024		
JP 2009233326	A	20091015	JP 2006108968	A	20001024	200969	E
			JP 200963647	A	20090316		

Priority Applications (no., kind, date): US 2000694217 A 20001023; AU 2005201675 A 20050421

Delivering drug, particularly teratogenic or other hazardous drug to patient involves generating prescription approval code to be retrieved by pharmacy before prescription is filled Technology Focus ...is probative of the onset of the adverse side effect. It also comprises genetic testing. The second set of information comprises a survey regarding the **patients behavior** and compliance with the risk avoidance measures. The survey is effected telephonically using an integrated voice response system. The patient has childbearing potential and the... **Extension Abstract**

B. Patent Files, Full-Text

```
  File 348:EUROPEAN PATENTS 1978-200936
         (c) 2009 European Patent Office
  File 349:PCT FULLTEXT 1979-2009/UB=20090827|UT=20090709
         (c) 2009 WIPO/Thomson

Set     Items   Description
S1      59929   ((SENSITIVE OR DANGEROUS OR MONITORED OR REGULATED OR RISKY
             OR CONTROLLED OR ADDICTIVE OR MOOD()ALTERING OR ILLEGAL OR H-
             ARD OR (HABIT OR ADDICTION)(1N)FORMING OR NARCOTI?ING OR HAZA-
             RDOUS)(3N)(PHARMACEUTIC? OR PHARMAECEUTIC? OR PHARMACO? OR PH-
             ARMAECO? OR DRUG OR DRUGS OR SUBSTANCE OR SUBSTANCES OR MEDIC-
             ATION? ? OR MEDICINE? ? OR PILLS OR MEDICAMENT? ? OR ANAESTHE-
             TIC OR PAINKILLER? ? OR PAIN()KILLER? ? OR STIMULANT? ?) OR N-
             ARCOTIC? ? OR OPIATE OR OPIATES OR OPIOID? ? OR BENZODIAZEPIN-
             ES OR HYDROCODONE)
S2      26066   S1 AND PY=1978:2002
S3      22051   S1 AND ((AC=US OR AC=US/PR) AND AY=1978:2002)
S4      31553   S2 OR S3
S5        221   S1(4N)(PRESCRIPTION? ? OR PRESCRIBE? ? OR PRESCRIBING OR W-
             RITTEN()(ORDER? ? OR INSTRUCTION? ? OR DIRECTION? ?) OR REQUE-
             ST? ? OR SCRIPT? ?)
S6         65   S5(5N)(TRACK? OR MONITOR? OR CONTROL? OR RESTRICT? OR SURV-
             EIL? OR MANAG? OR REGULAT? OR ENFORC? OR INHIBIT? OR LIMIT? OR
              RESTRAIN? OR CONSTRAIN? OR PROHIBIT? OR SUPERVIS? OR CHECKIN-
             G)
S7       4036   (ABUSE? ? OR ABUSIVE? OR ABUSING OR ILLEGAL? OR MISUSE OR -
             MIS()(USE OR USED OR USING) OR MISUSED OR MISUSING OR UNSCRUP-
             ULOUS?? OR UNETHICAL OR DRUG()(DEALER? ? OR DEALING) OR DISCI-
             PLINARY()ACTION? ? OR  MALTREATMENT? ? OR IMPROPER?? OR DISRE-
             PUTABLE OR MISTREATMENT? ? OR MISPRESCRIBING)
S8         348   S7(5N)(PATIENT? ? OR OUTPATIENT? ? OR INPATIENT? ? OR REQU-
             ESTER? ? OR PRESCRIPTION()HOLDER? ? OR CONSUMER? ? OR INDIVID-
             UAL? ? OR PERSON? ? OR CLIENT? ? OR PATRON? ? OR CUSTOMER? ? -
             OR BENEFICIARY? ? OR BENEFICIARIES)
S9          32   S7(5N)(PHARMACIST? ? OR PHARMAECIST? ? OR PHARMACOLOGIST? ?
              OR PHARMAECOLOGIST? ? OR DRUGGIST? ? OR CHEMIST? ? OR APOTHE-
```

```
            CAR? OR PHARMACOPOLIST? ? OR  PHYSICIAN? ? OR DOCTOR? ? OR  C-
            LINICIAN? ? OR SURGEON? ? OR PROVID?R? ? OR PRACTITIONER? ? OR
             PROFESSIONAL? ? OR SPECIALIST? ?)
S10      2090   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
            OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR SOLO OR RESTRIC-
            TED)(3N)(PHARMACY OR PHARMACIES OR FACILITY OR FACILITIES OR -
            DRUGGIST? ? OR CHEMIST? ? OR STATION? ? OR BUILDING? ? OR LOC-
            ATION? ? OR CENTER? ? OR CENTRE? ? OR CLINIC? ? OR HOSPITAL? ?
             OR OFFICE OR OFFICES OR ESTABLISHMENT? ? OR SITE OR HEAD()QU-
            ARTER? ? OR HEADQUARTER? ? OR HQ OR APOTHECAR? OR DRUGSTORE OR
             STORE)
S11      2465   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
            OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR MAINFRAME)(3N)(-
            DATABASE OR DATABASES OR DATABANK? ? OR DATAFILE? ?  OR DATA(-
            )(BASE OR BASES OR BANK OR BANKS) OR REPOSITOR? OR DB OR D()B
            OR DBMS OR RDBMS OR D()B()M()S OR PORTAL OR PORTALS OR COMPUT-
            ER? ? OR CPU OR SERVER OR SERVERS OR PROCESSOR? ?)
S12         4   S6 (20N) S7
S13         2   S6 (50N) (S8 OR S9)
S14         8   S6 (50N) (S10 OR S11)
S15        11   S12 OR S13 OR S14
S16        42   S5 (20N) S7
S17        11   S16 (30N) (S8 OR S9)
S18         0   S17 (30N) (S10 OR S11)
S19         0   S16 (30N) (S10 OR S11)
S20         0   S16 (60N) (S10 OR S11)
S21         6   S5 (10N) (S10 OR S11)
S22         0   S5 (10N) (S8 AND S9)
S23      1057   S4 (5N) S7
S24        36   S23 (20N) S5
S25         9   S24 (50N) (S8 OR S9)
S26         0   S24 (50N) (S10 OR S11)
S27        29   S4 ( 10N) S10
S28         0   S27 (40N) S7
S29         1   S27 (40N) S11
S30        10   (S17 OR S21 OR S25 OR S29) NOT S15
S31         4   AU=((REARDAN, D? OR REARDAN D? OR REARDAN(2N)D?) OR (ENEEL,
              P? OR ENEEL P? OR ENEEL(2N)P?) OR (GAGNE, B? OR GAGNE B? OR -
            GAGNE(2N)B?))
```

DIALOG(R)File 348: EUROPEAN PATENTS

15/3K/1 (Item 1 from file: 348)
00731437

PATIENT CARE AND COMMUNICATION SYSTEM
PATIENTENGESUNDHEITSVORSORGE- UND KOMMUNIKATIONSSYSTEM
SYSTEME D'ADMINISTRATION DE SOINS ET DE COMMUNICATION

Patent Assignee:

- **EXECUTONE INFORMATION SYSTEMS, INC.** (1852490)
  6 Thorndal Circle; Darien, CT 06820 (US)
  (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

Inventor:

- **CHACO, John**
  1 Great Meadow Road; Seymour, CT 06483; (US)
- **HERSH, Israel**
  175 Sairmont Terrace; Fairfield, CT 06432; (US)

- **ORLOVSKY, Dmitry**
  26 Tamanny Trail; Danbury, CT 06811; (US)
- **VINCENS, Joe**
  15 Roy Mountain Road; Prospect, CT 06712; (US)

Legal Representative:
- **Read, Matthew Charles et al (47911)**
  Venner Shipley & Co. 20 Little Britain; London EC1A 7DH; (GB)

	Country	Number	Kind	Date	
Patent	EP	689699	A1	19960103	(Basic)
	EP	689699	B1	19990428	
	WO	9422098		19940929	
Application	EP	94911420		19940228	
	WO	94US2114		19940228	
Priorities	US	33287		19930316	

If the individual is authorized to access the locker, step 2064 records the identifying information and the authorization information on the **central computer** 432. As each medicine container is removed from the locker, it is scanned by the bar-code reader. When the bar-code information has been scanned, the process changes a value in a memory location to indicate that the container may be removed.
The actual use of the **prescription medicines** may also be **monitored** from the information provided to the **central computer** 432. This information indicates the individuals who had access to the drug locker, the time they removed and returned the medicines, the patients to whom...

DIALOG(R)File 348: EUROPEAN PATENTS

15/3K/2 (Item 2 from file: 348)
00598239
A dispenser for use with a drug dispensing apparatus
Spender zur Anwendung in einer Vorrichtung zur Abgabe von Arzneimitteln
Distributeur pour usage dans un systeme de distribution de medicaments
Patent Assignee:
- **BAXTER INTERNATIONAL INC.** (318505)
  One Baxter Parkway; Deerfield, Illinois 60015 (US)
  (applicant designated states: DE;FR;GB;SE)

Inventor:
- **Blechl, Joseph**
  26036 West Lakeview; Ingleside, Illinois; (US)
- **Hadjimitsos, Panos**
  11 Amherst Court; Buffalo Grove, Illinois; (US)
- **Kurts, James R.**
  128 North Garfield; Mundelein, Illinois; (US)
- **Shimizu, Hiroyasu**
  517-37, Higashi Bessho; Ota-shi, Gunma 373; (JP)

- **Haraguchi, Manabu**
  50-8, Hinode, Oizumi-machi; Ora-gun, Gunma 370-05; (JP)

Legal Representative:
- **Lerwill, John et al (33011)**
  A.A. Thornton & Co. Northumberland House 303-306 High Holborn; London, WC1V 7LE; (GB)

	Country	Number	Kind	Date	
Patent	EP	597558	A2	19940518	(Basic)
	EP	597558	A3	19940608	
	EP	597558	B1	19980114	
Application	EP	93203615		19900525	
Priorities	JP	89132059		19890525	
	JP	90107295		19900423	

Specification: ...Initially, the controlled substances were shipped to medical facilities packaged in containers, such as bottles, jars, and the like. These containers were stored at a **central pharmacy location**. When a doctor required administration of a dose of a **controlled substance** to a patient, a **prescription** was written and a nurse was responsible for obtaining the dosage from the pharmacy and administering it to the patient.

15/3K/8 (Item 4 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

01033947
APPARATUS AND METHOD FOR CONSTRUCTING FORMULARIES
APPAREIL ET PROCEDE POUR ETABLIR DES NOMENCLATURES DE MEDICAMENTS
Patent Applicant/Patent Assignee:
- **MEDCO HEALTH SOLUTIONS INC**
  100 Parsons Pond Drive, Mailstop F3-19, Franklin Lakes, NJ 07417; US; US(Residence); US(Nationality)

Inventor(s):
- **BROWN Kenneth J**
  100 Parsons Pond Drive, Mailstop F3-19, Franklin Lakes, NJ 07417; US
- **TOBIN William D**
  100 Parsons Pond Drive, Mailstop F3-19, Franklin Lakes, NJ 07417; US
- **STETTIN Glen D**
  100 Parsons Pond Drive, Mailstop E2-04, Franklin Lakes, NJ 07417; US
- **DANIEL Roselin**
  100 Parsons Pond Drive, Mailstop E2-04, Franklin Lakes, NJ 07417; US

Legal Representative:
- **DONNER Irah H(et al)(agent)**
  Hale & Dorr LLP, 1455 Pennsylvania Avenue, N.W., Washington, DC 20004; US

	Country	Number	Kind	Date
Patent	WO	200362954	A2-A3	20030731
Application	WO	2003US1650		20030122
Priorities	US	2002349407		20020122
	US	2003337366		20030107

Detailed Description:
...etc. It is also possible for the CAE 112 to meet directly, or in person, with the user 124 (e.g., healthcare provider representative).

The **central computer** 1 18 of the prescription coverage provider 1 10 stores information pertaining to prescription products that can used in the formulary. The **prescription** products are typically **drugs** and/or **controlled substances** that are useable for medicinal purposes and/or treatments.
Such products are assigned specific identifiers known as a National Drug Code (NDQ identifier. New products...

15/3K/9 (Item 5 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00561819
PRESCRIPTION-CONTROLLED DATA COLLECTION SYSTEM AND METHOD
SYSTEME ET PROCEDE DE RECUEIL DE DONNEES COMMANDES PAR UNE ORDONNANCE
Patent Applicant/Patent Assignee:
- **VISIONARY MEDICAL INC**

Inventor(s):
- **SHEEHAN David M**
- **NITZBERG Mark J**
- **FITZGERALD Patrick J**

	Country	Number	Kind	Date
Patent	WO	200025192	A2	20000504
Application	WO	99US24965		19991022
Priorities	US	98105692		19981026

Detailed Description:
...a patient. In this implementation, a doctor at a remote location authorizes the patient to collect and transfer the data in a fashion analogous to **prescribing drugs**.
A **prescription controlled** data collection system 100 according to the present invention is illustrated in Figure 1. In overview, a prescribing party 104 writes a prescription 112 that authorizes a collecting party 122 to collect data and transfer the data to a **central server** II 0. The status of the prescription and data collected (block II 6) are available to the prescribing party 104 having access to server II...

15/3K/11 (Item 7 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00273922
PATIENT CARE AND COMMUNICATION SYSTEM
SYSTEME D'ADMINISTRATION DE SOINS ET DE COMMUNICATION
Patent Applicant/Patent Assignee:

- **EXECUTONE INFORMATION SYSTEMS INC**

Inventor(s):

- **CHACO John**
- **HERSH Israel**
- **ORLOVSKY Dmitry**
- **VINCENS Joe**

	Country	Number	Kind	Date
Patent	WO	9422098	A1	19940929
Application	WO	94US2114		19940228
Priorities	US	9333287		19930316

.on door 2011,
If the individual is authorized to access the
15 locker, step 2064 records the identifying information and
the authorization information on the **central computer**
432, As each medicine container is removed from the
locker, it is scanned by the bar-code reader, When the
bar-code information has been scanned, the process
20 changes a value in a memory location to indicate that the
container may be removed,
The actual use of the **prescription medicines**
may also be **monitored** from the information provided to
25 the **central computer** 432, This information indicates the
individuals who had access to the drug locker, the time
they removed and returned the medicines, the patients to
whom...

30/3K/1 (Item 1 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

01004829
METHODS FOR TREATING SUBSTANCE ABUSE WITH CHOLINESTERASE INHIBITORS
PROCEDES DE TRAITEMENT DE LA CONSOMMATION ABUSIVE DE SUBSTANCES PSYCHOACTIVES A L'AIDE D'INHIBITEURS DE LA CHOLINESTERASE
Patent Applicant/Patent Assignee:

- **EISAI CO LTD**
  Koishikawa 4-6-10, Bunkyo-Ku, Tokyo 112-8088; JP; JP(Residence); JP(Nationality); (For all designated states except: US)

Patent Applicant/Inventor:

- **PRATT Raymond**
  38 Meadow View Court, Leonia, NJ 07605; US; US(Residence); US(Nationality); (Designated only for: US)
- **IENI John**
  253 Ridgewood Avenue, Glen Ridge, NJ 07028; US; US(Residence); US(Nationality); (Designated only for: US)

Legal Representative:

- **GRIEFF Edward D(et al)(agent)**
  The Willard Office Building, 1455 Pennsylvania Avenue NW, Washington, DC 20004; US

	Country	Number	Kind	Date
Patent	WO	200332914	A2-A3	20030424
Application	WO	2002US32998		20021017
Priorities	US	2001329529		20011017

The invention provides methods for treating substance **abuse** in a **patient** by administering an effective amount of at least one cholinesterase inhibitor. The methods of the invention are applicable to any substances that are **abused** by **patients** or that may cause physical and/or psychological dependence (i.e., addiction). **Addictive substances** may be **prescription drugs** or street **drugs**. **Addictive substances** include, for example, alcohol, opioids, anxiolytic drugs, hypnotic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, benzodiazepines, and the like. Addictive substances include club drugs...

30/3K/9 (Item 9 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00563715
REMOTE PHYSICIAN AUTHENTICATION SERVICE
SERVICE D'AUTHENTIFICATION DE MEDECINS A DISTANCE
Patent Applicant/Patent Assignee:

- **PHYSICIAN VERIFICATION SERVICES INC**
- **MCCORMICK Douglas K**
- **DUBNER Robert J**

Inventor(s):

- **MCCORMICK Douglas K**
- **DUBNER Robert J**

	Country	Number	Kind	Date
Patent	WO	200027088	A2	20000511
Application	WO	99US22253		19990924

	Country	Number	Kind	Date
Priorities	US	98106838		19981103
	US	99248308		19990211

.S. regulations, other non-U.S.
national regulatory agencies currently maintain bans on direct-to-consumer advertising.
According to the World Health Organization (WHO), direct **consumer** promotion of **prescription drugs** is **illegal** except in the United States and Morocco.
Backimound: Marketiqg
The pharmaceutical industry spends more than $15 billion annually marketing to physicians in the United States...

30/3K/10 (Item 10 from file: 349)
DIALOG(R)File 349: PCT FULLTEXT

00438212
SYSTEM FOR DRUG AND HEALTH CARE SUPPLY DISTRIBUTION AND REPLENISHMENT
SYSTEME DE DISTRIBUTION ET DE RECHARGE POUR MEDICAMENTS ET FOURNITURES MEDICALES
Patent Applicant/Patent Assignee:

- **PYXIS CORPORATION**

Inventor(s):

- **LESTER Douglas D**
- **COLELLA Salvatore**
- **SWENSON David D**
- **BROADFIELD Laird**
- **DAFT H Thomas**
- **LAWRENCE Stephen M**
- **WIDENHOFER Gerald J**

	Country	Number	Kind	Date
Patent	WO	9828676	A2	19980702
Application	WO	97US22396		19971209
Priorities	US	96762041		19961209
	US	97867605		19970602

Detailed Description:
...program. The communication between the DDMs IS and
9
the health care provider's pharmacy software program of the present invention, may be accomplished through **hard** wiring the **drug** dispensing machines throughout the **facility** to a **central computer** 20 operatin(the pharmacy second software prograrn. Other suitable means, such as RF communication, to provide a cornmunications link between the drug dispensing machines and...

IV. Text Search Results from Dialog

A. NPL Files, Abstract

```
  File  35:Dissertation Abs Online 1861-2009/Aug
        (c) 2009 ProQuest Info&Learning
  File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13
        (c) 2002 Gale/Cengage
  File  65:Inside Conferences 1993-2009/Sep 08
        (c) 2009 BLDSC all rts. reserv.
  File   2:INSPEC 1898-2009/Aug W4
        (c) 2009 The IET
  File 474:New York Times Abs 1969-2009/Sep 08
        (c) 2009 The New York Times
  File 475:Wall Street Journal Abs 1973-2009/Sep 08
        (c) 2009 The New York Times
  File  99:Wilson Appl. Sci & Tech Abs 1983-2009/Aug
        (c) 2009 The HW Wilson Co.
  File 256:TecTrends 1982-2009/Aug W5
        (c) 2009 Info.Sources Inc. All rights res.
  File   5:Biosis Previews(R) 1926-2009/Dec W1
        (c) 2009 The Thomson Corporation
  File  73:EMBASE 1974-2009/Dec 15
        (c) 2009 Elsevier B.V.
  File 155:MEDLINE(R) 1950-2009/Dec 09
        (c) format only 2009 Dialog
  File  34:SciSearch(R) Cited Ref Sci 1990-2009/Dec W1
        (c) 2009 The Thomson Corp
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
        (c) 2006 The Thomson Corp
  File  74:Int.Pharm.Abs 1970-2009/Sep B1
        (c) 2009 The Thomson Corporation
  File  42:Pharm. News Index 1974-2009/Nov W3
        (c) 2009 ProQuest Info&Learning

Set     Items   Description
S1     786496   ((SENSITIVE OR DANGEROUS OR MONITORED OR REGULATED OR RISKY
                 OR CONTROLLED OR ADDICTIVE OR MOOD()ALTERING OR ILLEGAL OR H-
                ARD OR (HABIT OR ADDICTION)(1N)FORMING OR NARCOTI?ING OR HAZA-
                RDOUS)(3N)(PHARMACEUTIC? OR PHARMAECEUTIC? OR PHARMACO? OR PH-
                ARMAECO? OR DRUG OR DRUGS OR SUBSTANCE OR SUBSTANCES OR MEDIC-
                ATION? ? OR MEDICINE? ? OR PILLS OR MEDICAMENT? ? OR ANAESTHE-
                TIC OR PAINKILLER? ? OR PAIN()KILLER? ? OR STIMULANT? ?) OR N-
                ARCOTIC? ? OR OPIATE OR OPIATES)
S2      3859    S1(4N)(PRESCRIPTION? ? OR PRESCRIBE? ? OR PRESCRIBING OR W-
                RITTEN()(ORDER? ? OR INSTRUCTION? ? OR DIRECTION? ?) OR REQUE-
                ST? ? OR SCRIPT? ?)
S3      1747    S2(5N)(TRACK? OR MONITOR? OR CONTROL? OR RESTRICT? OR SURV-
                EIL? OR MANAG? OR REGULAT? OR ENFORC? OR INHIBIT? OR LIMIT? OR
                 RESTRAIN? OR CONSTRAIN? OR PROHIBIT? OR SUPERVIS? OR CHECKIN-
                G)
S4      3865    (ABUSE? ? OR ABUSIVE? OR ABUSING OR ILLEGAL? OR MISUSE OR -
                MIS()(USE OR USED OR USING) OR MISUSED OR MISUSING OR UNSCRUP-
                ULOUS?? OR UNETHICAL OR DRUG()(DEALER? ? OR DEALING) OR DISCI-
                PLINARY()ACTION? ? OR  MALTREATMENT? ? OR IMPROPER?? OR DISRE-
                PUTABLE OR MISTREATMENT? ?)(4N)(IDENTIF? OR MONITOR? OR ANALY-
                ?E? ? OR ANALYSIS OR ANALY?ING OR WARN? ? OR WARNING? ? OR RE-
                D()FLAG OR ALERT? OR DETECT? OR REVEAL? OR DISCOVER? OR EXPOS-
                E? ? OR EXPOSING OR UNCOVER? OR RECOGNI?E? ? OR RECOGNI?ING OR
```

```
             RECOGNITION)
S5       12330   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
             ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
             EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
             ACKGROUND? ?)(3N)(PATIENT? ? OR OUTPATIENT? ? OR INPATIENT? ?
             OR REQUESTER? ? OR PRESCRIPTION()HOLDER? ? OR CONSUMER? ? OR -
             INDIVIDUAL? ? OR PERSON? ? OR CLIENT? ? OR PATRON? ? OR CUSTO-
             MER? ?)
S6        2064   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
             ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
             EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
             ACKGROUND? ? OR PRECENDENT? ? OR CREDENTIAL? ?)(3N)(PHARMACIS-
             T? ? OR PHARMAECIST? ? OR PHARMACOLOGIST? ? OR PHARMAECOLOGIS-
             T? ? OR DRUGGIST? ? OR CHEMIST? ? OR APOTHECAR? OR PHARMACOPO-
             LIST? ? OR  PHYSICIAN? ? OR DOCTOR? ? OR  CLINICIAN? ? OR SUR-
             GEON? ? OR PROVID?R? ? OR PRACTITIONER? ? OR PROFESSIONAL? ? -
             OR SPECIALIST? ?)
S7        2888   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
             OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR SOLO OR RESTRIC-
             TED)(3N)(PHARMACY OR PHARMACIES OR FACILITY OR FACILITIES OR -
             DRUGGIST? ? OR CHEMIST? ? OR STATION? ? OR BUILDING? ? OR LOC-
             ATION? ? OR CENTER? ? OR CENTRE? ? OR CLINIC? ? OR HOSPITAL? ?
              OR OFFICE OR OFFICES OR ESTABLISHMENT? ? OR SITE OR HEAD()QU-
             ARTER? ? OR HEADQUARTER? ? OR HQ OR APOTHECAR? OR DRUGSTORE OR
              STORE)
S8        1712   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
             OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR MAINFRAME)(3N)(-
             DATABASE OR DATABASES OR DATABANK? ? OR DATAFILE? ?  OR DATA(-
             )(BASE OR BASES OR BANK OR BANKS) OR REPOSITOR? OR DB OR D()B
             OR DBMS OR RDBMS OR D()B()M()S OR PORTAL OR PORTALS OR COMPUT-
             ER? ? OR CPU OR SERVER OR SERVERS)
S9           3   AU=((REARDAN, D? OR REARDAN D? OR REARDAN(2N)D?) OR (ENEEL,
              P? OR ENEEL P? OR ENEEL(2N)P?) OR (GAGNE, B? OR GAGNE B? OR -
             GAGNE(2N)B?))
S10         64   S3 AND S4
S11         10   S10 AND S5
S12          3   S11 AND S6
S13          0   S10 AND S7
S14          1   S10 AND S8
S15          1   (S11 OR S14) NOT PY>2002
S16         38   S3 AND S7
S17          1   S16 AND (DATABASE? ? OR DATA()BASE? ? OR REPOSITOR? OR DB -
            OR D()B OR DBMS OR D()B()M()S)
S18         26   S2 AND S4 AND (S5 OR S6)
S19          0   S18 AND (S7 OR S8)
S20         22   (S16 OR S18) NOT (S15 OR PY>2002)
S21         19   RD  (unique items)
```

15/3,K/1 (Item 1 from file: 74)
DIALOG(R)File 74: Int.Pharm.Abs

00166057 27-02154
CONTROLLED SUBSTANCES UTILIZATION REVIEW TO DETECT ABUSE POTENTIAL
Strachota, A.; Wilkins, N.; Smith, G.; O'Brien, M.
PARTNERS National Health Plans, 7760 France Avenue South, Minneapolis, MN 55435, USA
ASHP Midyear Clinical Meeting, V24, (Dec), pHMO-3, 1989
Abstract of Meeting Presentation

Language: English **Record Type:** Abstract
CONTROLLED SUBSTANCES UTILIZATION REVIEW TO DETECT ABUSE POTENTIAL
...CSUR) was performed screening prescription claims processed from a network model HMO over a 12 month interval. The goal was to reduce the number of **patients** with **profiles** suggestive of drug abuse potential. Criteria indicating potential patient overuse and used for contacting the prescribing physician were: 1. Multiple physicians visited to obtain controlled... ...in 27% of the responses. In 10% of the responses received, the physician was no longer a plan provider. The review raised the awareness of **controlled substance prescribing** to these physicians, was well received and had a positive impact in one-quarter of the responses returned.
Webster

21/3,K/16 (Item 9 from file: 34)
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

05096113 **Genuine Article#:** TP781 **No. References:** 34
Title: EFFECTIVENESS OF NOTIFICATION AND GROUP EDUCATION IN MODIFYING PRESCRIBING OF REGULATED ANALGESICS
Author: ANDERSEN JF; MCEWAN EL; HRUDEY WP
Corporate Source: BRITISH COLUMBIA MINIST HLTH & MINIST RESPONSIBLE,ADULT CLIN & ADDICT SERV BRANCH,3RD FLOOR/VICTORIA/BC V8T 4J1/CANADA/; UNIV VICTORIA,DEPT PSYCHOL/VICTORIA/BC/CANADA/; UNIV BRITISH COLUMBIA,FAC MED,DEPT HLTH CARE & EPIDEMIOL/VANCOUVER/BC/CANADA/
Journal: CANADIAN MEDICAL ASSOCIATION JOURNAL , 1996 , V 154 , N1 (JAN 1) , P 31-39
ISSN: 0820-3946
Language: ENGLISH **Document Type:** ARTICLE (Abstract Available)
Abstract: ...Nonacademic primary care practices in British Columbia.

Participants: Fifty-four physicians randomly selected from a group of 100 physicians who had written a number of **prescriptions** for **regulated drugs** more than than two standard deviations above the mean number of prescriptions written for such drugs in 1992. Any physician who was unable to participate...
Descriptors:
Identifiers: ...CONTROLLED TRIAL; **PRIMARY** CARE; **OFFICE** PRACTICE; POLYPHARMACY; OUTREACH; BEHAVIOR; FEEDBACK
Research Fronts:

21/3,K/17 (Item 1 from file: 74)
DIALOG(R)File 74: Int.Pharm.Abs

00292283 35-13192
DRUG DIVERSION BY HEALTH PROFESSIONALS
Burke, J. J.; Fitzgerald, M. E.
Cincinnati PD Pharmaceutical Unit, 801 B West 8th Street, Suite 319, Cincinnati, OH 45203, USA
Internet: Burke@choice.net

ASHP Midyear Clinical Meeting, V33, (Dec), pPI-73, 1998
Abstract of Meeting Presentation
Language: English **Record Type:** Abstract

The **illegal** diversion of **prescription drugs** in the health care facility is a national problem that, at one time or another, affects all institutions. Being familiar with the top pharmaceutical drugs of abuse, and how they are used, is the first step in reducing these incidents. Knowing the **profile** of the health **professional** diverting the drugs, and their methods, can offer assistance in identifying the drug dependent person. Utilizing several methods of prevention can make diverting pharmaceuticals in... ...toward rehabilitation of the offender.

Learning objectives: 1. Identify the top prescription drugs of abuse, including how they are used, and their values in the **illegal** market. 2. **Identify** the profile of the prescription drug dependent health professional and methods of drug diversion. 3. Identify specific avenues to enhance the prevention of drug diversion in the health facility.

Self-assessment questions: True or False: 1. Hydrocodone is the most abused pharmaceutical drug. 2. Absenteeism is part of the typical **profile** of the health **professional** diverting prescription drugs. 3. Drug diversion education for the health facility staff assists in reducing incidents of the theft of pharmaceuticals.

Answers: 1. T; 2...

Descriptors: ...diversion, health professionals; Health professions -- drug diversion, overview; Drug diversion -- health professions, overview; Crime -- drug diversion, health professionals; Prescriptions -- drug diversion, health professionals; Drug abuse -- **prescriptions**, **drug diversion**; **Controlled substances** -- abuse, **drug** diversion

21/3,K/19 (Item 3 from file: 74)
DIALOG(R)File 74: Int.Pharm.Abs

00193099 29-00022

ACCEPTANCE BY PHYSICIANS OF RECOMMENDED DRUG REGIMEN MODIFICATIONS

Poole, T. A.; Petry, M. L.
Department of Pharmacy, Manatee Memorial Hospital, 206 Second Street East, Bradenton, FL 34208, USA
ASHP Midyear Clinical Meeting, V26, (Dec), pP-179D, 1991
Abstract of Meeting Presentation
Language: English **Record Type:** Abstract

...attached to the outside of the patient's chart are in use for ranitidine, cefotaxime, ceftazidime, tobramycin, cefoxitin, and ceftriaxone. On a daily basis, the **Pharmacy** computer data **base** is queried to identify patients with orders for the monitored drugs. Using these data, the patient's pharmacy profile and chart are reviewed and a determination is made whether to sticker the chart.

Inappropriate **prescribing** of the **monitored drugs** has decreased significantly since the inception of the program; physician acceptance of the program has been excellent. Through our passive method of intervention using recommended..

B. NPL Files, Full-text

```
  File  15:ABI/Inform(R) 1971-2009/Sep 07
        (c) 2009 ProQuest Info&Learning
  File   9:Business & Industry(R) Jul/1994-2009/Sep 05
        (c) 2009 Gale/Cengage
  File 610:Business Wire 1999-2009/Sep 08
        (c) 2009 Business Wire.
  File 810:Business Wire 1986-1999/Feb 28
        (c) 1999 Business Wire
  File 275:Gale Group Computer DB(TM) 1983-2009/Aug 07
        (c) 2009 Gale/Cengage
  File 624:McGraw-Hill Publications 1985-2009/Sep 08
        (c) 2009 McGraw-Hill Co. Inc
  File 621:Gale Group New Prod.Annou.(R) 1985-2009/Jul 30
        (c) 2009 Gale/Cengage
  File 636:Gale Group Newsletter DB(TM) 1987-2009/Aug 13
        (c) 2009 Gale/Cengage
  File 613:PR Newswire 1999-2009/Sep 08
        (c) 2009 PR Newswire Association Inc
  File 813:PR Newswire 1987-1999/Apr 30
        (c) 1999 PR Newswire Association Inc
  File  16:Gale Group PROMT(R) 1990-2009/Aug 13
        (c) 2009 Gale/Cengage
  File 160:Gale Group PROMT(R) 1972-1989
        (c) 1999 The Gale Group
  File 634:San Jose Mercury  Jun 1985-2009/Sep 01
        (c) 2009 San Jose Mercury News
  File 148:Gale Group Trade & Industry DB 1976-2009/Aug 20
        (c) 2009 Gale/Cengage
  File  20:Dialog Global Reporter 1997-2009/Sep 08
        (c) 2009 Dialog
  File 149:TGG Health&Wellness DB(SM) 1976-2009/Nov W2
        (c) 2009 Gale/Cengage
  File 444:New England Journal of Med. 1985-2009/Dec W1
        (c) 2009 Mass. Med. Soc.
  File 129:PHIND(Archival) 1980-2009/Dec W2
        (c) 2009 Informa UK Ltd
  File 130:PHIND(Daily & Current) 2009/Dec 14
        (c) 2009 Informa UK Ltd
  File 455:Drug News & Perspectives 1992-2005/Aug
        (c) 2005 Prous Science

Set     Items   Description
S1     481561   ((SENSITIVE OR DANGEROUS OR MONITORED OR REGULATED OR RISKY
              OR CONTROLLED OR ADDICTIVE OR MOOD()ALTERING OR ILLEGAL OR H-
             ARD OR (HABIT OR ADDICTION)(1N)FORMING OR NARCOTI?ING OR HAZA-
             RDOUS)(3N)(PHARMACEUTIC? OR PHARMAECEUTIC? OR PHARMACO? OR PH-
             ARMAECO? OR DRUG OR DRUGS OR SUBSTANCE OR SUBSTANCES OR MEDIC-
             ATION? ? OR MEDICINE? ? OR PILLS OR MEDICAMENT? ? OR ANAESTHE-
             TIC OR PAINKILLER? ? OR PAIN()KILLER? ? OR STIMULANT? ?) OR N-
             ARCOTIC? ? OR OPIATE OR OPIATES OR OPIOID? ? OR BENZODIAZEPIN-
             ES OR HYDROCODONE)
S2     188468   S1 NOT PY>2002
S3       4840   S2(4N)(PRESCRIPTION? ? OR PRESCRIBE? ? OR PRESCRIBING OR W-
             RITTEN()(ORDER? ? OR INSTRUCTION? ? OR DIRECTION? ?) OR REQUE-
             ST? ? OR SCRIPT? ?)
S4      70239   (ABUSE? ? OR ABUSIVE? OR ABUSING OR ILLEGAL? OR MISUSE OR -
             MIS()(USE OR USED OR USING) OR MISUSED OR MISUSING OR UNSCRUP-
             ULOUS?? OR UNETHICAL OR DRUG()(DEALER? ? OR DEALING) OR DISCI-
```

```
            PLINARY()ACTION? ? OR  MALTREATMENT? ? OR IMPROPER?? OR DISRE-
            PUTABLE OR MISTREATMENT? ? OR MISPRESCRIBING)
S5       7738   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
            ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
            EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
            ACKGROUND? ?)(3N)(PATIENT? ? OR OUTPATIENT? ? OR INPATIENT? ?
            OR REQUESTER? ? OR PRESCRIPTION()HOLDER? ? OR CONSUMER? ? OR -
            INDIVIDUAL? ? OR PERSON? ? OR CLIENT? ? OR PATRON? ? OR CUSTO-
            MER? ?)
S6       3092   (PATTERN? ? OR HABIT? ? OR RECORD? ? OR HISTORY OR HISTORI-
            ES OR BEHAVIOR? ? OR BEHAVIOUR? ? OR PROFILE OR PROFILES OR R-
            EPORT? ? OR DOCUMENTATION OR FILE OR FILES OR HISTORIC?? OR B-
            ACKGROUND? ? OR PRECENDENT? ? OR CREDENTIAL? ?)(3N)(PHARMACIS-
            T? ? OR PHARMAECIST? ? OR PHARMACOLOGIST? ? OR PHARMAECOLOGIS-
            T? ? OR DRUGGIST? ? OR CHEMIST? ? OR APOTHECAR? OR PHARMACOPO-
            LIST? ? OR  PHYSICIAN? ? OR DOCTOR? ? OR  CLINICIAN? ? OR SUR-
            GEON? ? OR PROVID?R? ? OR PRACTITIONER? ? OR PROFESSIONAL? ? -
            OR SPECIALIST? ?)
S7       4055   (CENTRAL OR EXCLUSIVE OR MAIN OR MASTER OR PRIMARY OR BASE
            OR HOMEBASE OR CENTRALI?ED OR  CONTROLLING OR SOLO OR RESTRIC-
            TED)(3N)(PHARMACY OR PHARMACIES OR FACILITY OR FACILITIES OR -
            DRUGGIST? ? OR CHEMIST? ? OR STATION? ? OR BUILDING? ? OR LOC-
            ATION? ? OR CENTER? ? OR CENTRE? ? OR CLINIC? ? OR HOSPITAL? ?
             OR OFFICE OR OFFICES OR ESTABLISHMENT? ? OR SITE OR HEAD()QU-
            ARTER? ? OR HEADQUARTER? ? OR HQ OR APOTHECAR? OR DRUGSTORE OR
             STORE)
S8         96   S7(5N)(DATABASE OR DATABASES OR DATABANK? ? OR DATAFILE? ?
            OR DATA()(BASE OR BASES OR BANK OR BANKS) OR REPOSITOR? OR DB
            OR D()B OR DBMS OR RDBMS OR D()B()M()S OR PORTAL OR PORTALS -
            OR COMPUTER? ? OR CPU OR SERVER OR SERVERS OR PROCESSOR? ?)
S9       1185   S3 (15N) S4
S10        29   S9 (20N) S5
S11         1   S10 (20N) S6
S12         3   S9 (20N) S6
S13         0   (S10 OR S12) (20N) S8
S14         0   (S10 OR S12) (S)S8
S15         0   (S10 OR S12)(S) S7
S16      1631   S3(5N)(TRACK? OR MONITOR? OR CONTROL? OR RESTRICT? OR SURV-
            EIL? OR MANAG? OR REGULAT? OR ENFORC? OR INHIBIT? OR LIMIT? OR
             RESTRAIN? OR CONSTRAIN? OR PROHIBIT? OR SUPERVIS? OR CHECKIN-
            G)
S17      5935   S4(4N)(IDENTIF? OR MONITOR? OR ANALY?E? ? OR ANALYSIS OR A-
            NALY?ING OR WARN? ? OR WARNING? ? OR RED()FLAG OR ALERT? OR D-
            ETECT? OR REVEAL? OR DISCOVER? OR EXPOSE? ? OR EXPOSING OR UN-
            COVER? OR RECOGNI?E? ? OR RECOGNI?ING OR RECOGNITION)
S18        37   S16 (S) S17
S19         9   S18 (S)(S5 OR S6)
S20         1   S18 (S)S7
S21        11   S11 OR S12 OR S19 OR S20
S22        10   RD  (unique items)
S23         0   AU=((REARDAN, D? OR REARDAN D? OR REARDAN(2N)D?) OR (ENEEL,
             P? OR ENEEL P? OR ENEEL(2N)P?) OR (GAGNE, B? OR GAGNE B? OR -
            GAGNE(2N)B?))
```

22/3,K/1 (Item 1 from file: 636)
DIALOG(R)File 636: Gale Group Newsletter DB(TM)

01825163 **Supplier Number:** 43098337 **(USE FORMAT 7 FOR FULLTEXT)**
HOUSE BILLS
Health Legislation & Regulation , p N/A

June 24 , 1992
Language: English **Record Type:** Fulltext
Document Type: Newsletter ; Trade
Word Count: 275

-

H.R.5051. To prevent and **detect illegal** and inappropriate drug distribution leading to increased health costs and drug abuse by allowing information on **prescription** of **drugs** that are **controlled substances** in schedules II, III, and IV, to be electronically transmitted to and collected by **central repositories** of designated state health agencies to improve the confidentiality of **patient records**, and to ensure improved treatment of pain, mental health-related needs and other patient prescribing needs. (Stark) Commerce.

H.R.5052. To provide for the...

22/3,K/2 (Item 2 from file: 636)
DIALOG(R)File 636: Gale Group Newsletter DB(TM)

01808643 **Supplier Number:** 43051875 **(USE FORMAT 7 FOR FULLTEXT)**
New Bills in Congress: SENATE BILLS AND HOUSE BILLS
Health Manager's Update , p N/A
June 3 , 1992
Language: English **Record Type:** Fulltext
Document Type: Magazine/Journal ; Trade
Word Count: 596

-

...affordable health insurance is available to all citizens through a Unimed Program. (Ford) Ways & Means, Commerce, and Education & Labor.

H.R.5051. To prevent and **detect illegal** and inappropriate drug distribution leading to increased health costs and drug abuse by allowing information on **prescription** of **drugs** that are **controlled substances** in schedules II, III, and IV, to be electronically transmitted to and collected by **central repositories** of designated state health agencies to improve the confidentiality of **patient records**, and to ensure improved treatment of pain, mental health-related needs and other patient prescribing needs. (Stark) Commerce.

H.R.5052. To provide for the...

22/3,K/3 (Item 3 from file: 636)
DIALOG(R)File 636: Gale Group Newsletter DB(TM)

01790574 **Supplier Number:** 43001457 **(USE FORMAT 7 FOR FULLTEXT)**

HEARING FOR US FDA BILL THIS MONTH?
Marketletter , p N/A

May 18 , 1992
Language: English **Record Type:** Fulltext
Document Type: Magazine/Journal; Newsletter ; Trade
Word Count: 329

-

...Stark has introduced his Prescription Accountability & Patient Care Improve-ment Act (HR 5051) into the House.
The aim of this legislation is to prevent and **detect illegal** and inappropriate drug distribution leading to increased health costs and drug abuse, by allowing information on **prescriptions** of **controlled substances** in Schedules II, III and IV to be electronically collected by "central repositories of designated state health agencies." This will improve the confidentiality of **patient records**, and ensure improved treatment of pain and other patient needs, says the bill.

22/3,K/5 (Item 1 from file: 20)
DIALOG(R)File 20: Dialog Global Reporter

09622045 **(USE FORMAT 7 OR 9 FOR FULLTEXT)**
(Editorial) Doctors take to the streets
KOREA HERALD
February 18, 2000
Journal Code: FKHD **Language:** English **Record Type:** FULLTEXT
Word Count: 747
(USE FORMAT 7 OR 9 FOR FULLTEXT)

...monitored. Otherwise, the misuse or even alteration of prescriptions at drugstores can occur. Such malpractice may have tragic effects. Pharmacists, for instance, are required to **report** to **patients** ' clinics or hospitals in the event they substitute some of the prescribed medicines, but whether they will comply with the requirement is a matter that...

22/3,K/6 (Item 1 from file: 149)
DIALOG(R)File 149: TGG Health&Wellness DB(SM)

01313805 **Supplier Number:** 11666494 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Responsible prescribing of controlled substances.
Voth, Eric A.; Dupont, Robert L.; Voth, Harold M.
American Family Physician , v44 , n5 , p1673(6)
Nov ,
1991
Publication Format: Magazine/Journal
ISSN: 0002-838X
Language: English

Record Type: Fulltext; Abstract **Target Audience:** Professional
Word Count: 2141 **Line Count:** 00254
Abstract: Physicians' prescribing habits are carefully **regulated** when **controlled substances** are involved. **Disciplinary actions** for **improper** prescribing can range from loss of prescribing privileges to loss of one's medical license. Data from the Drug **Abuse Warning** Network **reveal** that, in 1987, 14 of the 20 most common causes of drug overdose, dependence or adverse effects were caused either by prescription or over-the...
Abstract:
...have two incentives for obtaining drugs; they may abuse the prescribed controlled substances themselves or sell them to other addicts.
Avoiding Problems in Practice
The **detection** of prescription **abuse** may require an attitude shift on the part of the physician. Physicians tend to trust their patients and therefore may be at risk for manipulation. When a patient **requests** a **controlled substance**, it may be prudent to question the validity of the **patient**'s medical **history** and to "read between the lines."
Identifying the potential overdose victim can be difficult. Patients who are confused or mildly demented may accidentally take medications...

22/3,K/7 (Item 2 from file: 149)
DIALOG(R)File 149: TGG Health&Wellness DB(SM)

01313366 **Supplier Number:** 11198422 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Institution of a 'no narcotics' policy for after-hours telephone calls.
Madlon-Kay, Diane J.
Journal of Family Practice , v33 , n1 , p92(3)
July ,
1991
Publication Format: Magazine/Journal
ISSN: 0094-3509
Language: English
Record Type: Fulltext; Abstract **Target Audience:** Professional
Word Count: 1569 **Line Count:** 00192
...been previously diagnosed as substance abusers by their clinic physicians. Five patients' charts revealed multiple requests for controlled medications but no specific diagnosis of substance **abuse.**
The 28 patients **identified** as substance abusers did not differ significantly from nonabusers in terms of age, sex, **primary clinic**, day of call, symptom, or wether a specific medication was requested.
Eight of the ten residents completed a questionnaire about their experience with the "no...

22/3,K/8 (Item 3 from file: 149)
DIALOG(R)File 149: TGG Health&Wellness DB(SM)

01260740 **Supplier Number:** 10841835
Intravenous methylphenidate abuse: prototype for prescription drug abuse.
Parran, Theodore Vandoren, Jr.; Jasinski, Donald R.
Archives of Internal Medicine , v151 , n4 , p781(3)
April ,
1991
Document Type: evaluation **Publication Format:** Magazine/Journal
ISSN: 0003-9926
Language: English
Record Type: Abstract **Target Audience:** Professional

Abstract: ...of its effects. As methylphenidate has been prescribed more frequently of late for hyperactive children and those with attention-deficit disorder, more cases of its **abuse** have been **recognized**. A series of 22 patients who were known methylphenidate abusers were described. Nine of these had children who were on methylphenidate for hyperactivity. All of these **patients** had long **histories** of drug abuse; 21 of them used the methylphenidate intravenously. All had complications attributable to their use of the drug. Among these were weight loss... ...cause the various types of lung disease seen. Of note is the fact that the methylphenidate abused by these patients was obtained solely through physicians' **prescriptions**. Since this is a **controlled substance**, educating physicians to recognize drug-seeking behavior and requiring such devices as triplicate prescription forms with meticulous record-keeping are among the mechanisms necessary to...
Abstract:

22/3,K/9 (Item 4 from file: 149)
DIALOG(R)File 149: TGG Health&Wellness DB(SM)

01193074 **Supplier Number:** 08134753 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Help for impaired physicians.
McDermott, Robert M.; Samkoff, J.
Physician Executive , v15 , n1 , p26(4)
Jan-Feb ,
1989
Publication Format: Magazine/Journal
ISSN: 0898-2759
Language: English
Record Type: Fulltext **Target Audience:** Professional
Word Count: 2656 **Line Count:** 00224
...so-called geographical cure"). State impaired physician programs are generally in a better position to provide ongoing monitoring than are hospital-based programs, and will **report** on the **physician**'s progress in treatment to the appropriate person at the physician's workplace. Hospitals should consider making loans available to cover any treatment costs not...

...impaired physician program assists in formulating after care plans, monitors compliance with the terms of the plan (including attendance at support group meetings and urine **monitoring** for **abuse** of drugs, in the case of chemical dependence), and maintains communication

with the treating physician, with the therapist, with the person monitoring the recovering physician...Schedule II and III drugs by physicians recovering from chemical dependence should be monitored by the designated clinical supervisor. The recovering physician should refrain from **prescribing** any **controlled drugs** until privileges are fully reinstated. The physician should agree not to use such drugs unless they are prescribed by another physician for a legitimate reason...

22/3,K/10 (Item 5 from file: 149)
DIALOG(R)File 149: TGG Health&Wellness DB(SM)

01118602 **Supplier Number:** 05201437 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Pharmacists say no to prescription forgery. (includes related articles)
Weiss, Barbara
Drug Topics , v131 , p36(7)
Aug 17 ,
1987
Publication Format: Magazine/Journal
ISSN: 0012-6616
Language: English
Record Type: Fulltext **Target Audience:** Trade
Word Count: 3991 **Line Count:** 00369
...clinic is careful about taking too many Rxs from certain doctors in the "nerve' and "pain' categories. Other pharmacists watch out for doctors who overprescribe **narcotics** or otherwise **abuse** their **prescribing** privileges.

Pharmacists also keep an eye out for patients who are likely to be abusers. Many **pharmacists** keep **patient profiles** to help them weed out the "shoppers'--patients who go to many doctors for the same medication. And patients with known reputations as drug abusers...

V. Additional Resources Searched

A. ProQuest

No documents found for: *(((sensitive or monitored or controlled or regulated or addictive or illegal or "habit forming" or narcotizing) w/3 (drug? or pharmaceutical? or pharmaeceutical? or substance? or medication or medicine?)) or narcotic? or opioid? or opiate?) W/3 (prescription? or prescribe? or prescribing) W/3 TEXT((track* or monitor* or control* or restrict* or surveil* or manag* or regulat* or enforc* or inhibit* or limit* or restrain* or constrain* or prohibit* or supervis* or checking)) AND TEXT((abuse? or abuser? or abusive* or abusing or misuse or misused or misusing or unscrupulous* or misprescribing)) AND TEXT((central or exclusive or main or master or primary or base or homebase or centrali?ed or controlling or solo or restricted or mainframe) w/3 (database or databases)) AND PDN(<12/17/2002)*

No documents found for: *(((sensitive or monitored or controlled or regulated or addictive or illegal or "habit forming" or narcotizing) w/3 (drug? or pharmaceutical? or pharmaeceutical? or substance? or medication or medicine?)) or narcotic? or opioid? or opiate?) W/3 (prescription? or prescribe? or prescribing) W/3 TEXT((track* or monitor* or control* or restrict* or surveil* or manag* or regulat* or enforc* or inhibit* or limit* or restrain* or constrain* or prohibit* or supervis* or checking)) AND TEXT((abuse? or abuser? or abusive* or abusing or misuse or misused or misusing or unscrupulous* or misprescribing)) AND TEXT((central or exclusive or main or master or primary or base or homebase or centrali?ed or controlling or solo or restricted) w/3 (pharmacy or pharmacies or facility or facilities or druggist? or chemist? or location? or hospital? or apothecar*)) AND PDN(<12/17/2002)*

No documents found for: *(((sensitive or monitored or controlled or regulated or addictive or illegal or "habit forming" or narcotizing) w/3 (drug? or pharmaceutical? or pharmaeceutical? or substance? or medication or medicine?)) or narcotic? or opioid? or opiate?) W/3 TEXT(prescription? or prescribe? or prescribing) W/3 TEXT((track* or monitor* or control* or restrict* or surveil* or manag* or regulat* or enforc* or inhibit* or limit* or restrain* or constrain* or prohibit* or supervis* or checking)) AND TEXT((abuse? or abuser? or abusive* or abusing or misuse or misused or misusing or unscrupulous* or misprescribing)) AND PDN(<12/17/2002)*

12 documents found for: *(((sensitive or monitored or controlled or regulated or addictive or illegal or "habit forming" or narcotizing) w/3 (drug? or pharmaceutical? or pharmaeceutical? or substance? or medication or medicine?)) or narcotic? or opioid? or opiate?) AND TEXT(prescription? or prescribe? or prescribing) AND TEXT((track* or monitor* or control* or restrict* or surveil* or manag* or regulat* or enforc* or inhibit* or limit* or restrain* or constrain* or prohibit* or supervis* or checking)) AND TEXT((abuse? or abuser? or abusive* or abusing or misuse or misused or misusing or unscrupulous* or misprescribing)) AND TEXT((central or exclusive or main or master or primary or base or homebase or centrali?ed or controlling or solo or restricted or mainframe) w/3 (database or databases or repositor*)) AND PDN(<12/17/2002)*

N.B. looks into program to monitor prescription drugs

BOBBI-JEAN MACKINNON. **New Brunswick Telegraph Journal**. Saint John, N.B.: Jun 1, 2002.

Abstract (Summary)

Health Minister Elvy Robichaud will ask staff already reviewing the prescription drug plan to look at the jury's recommendation as part of their mandate. Some of the other recommendations included: implementing a triplicate prescription program for narcotics, with one copy each for the physician, pharmacist and the College of Physicians and Surgeons; reinstating the position of a federal narcotics inspector who travels from pharmacy to pharmacy gathering information about possible cases of overprescribing by doctors or drug abuse by patients; and making it mandatory for pharmacies not to fill prescriptions for narcotics more than one day early.

The province will consider developing a prescription drug monitoring program, as recommended by a coroner's jury this week.

Health Minister Elvy Robichaud will ask staff already reviewing the prescription drug plan to look at the jury's recommendation as part of their mandate.

He expects a report by September.

The four-day coroner's inquest into the prescription overdose death of Stephen Beshara, 20, of Rothesay, came up with 17 recommendations to prevent similar deaths.

Some of the other recommendations included: implementing a triplicate prescription program for narcotics, with one copy each for the physician, pharmacist and the College of Physicians and Surgeons; reinstating the position of a federal narcotics inspector who travels from pharmacy to pharmacy gathering information about possible cases of overprescribing by doctors or drug abuse by patients; and making it mandatory for pharmacies not to fill prescriptions for narcotics more than one day early.

Mr. Beshara died in his sleep on Dec. 19, 2000. Autopsy results revealed several prescription drugs in his system, including Valium and Dilaudid, a powerful and addictive painkiller. Mr. Beshara had legitimate prescriptions for the drugs - all from Dr. Joe McLaughlin, of Quispamsis.

Asked by reporters whether he thought the idea of a monitoring program made sense, Mr. Robichaud said: Yes, yes. It always makes sense and it's always been something we wanted to do."

But it comes down to funding, he said, with estimates ranging from $50 to $100 million to develop a real-time central computer database of prescription information all pharmacies can access. "Definitely there is an intention to do that, but with the resources we have, it's to do what is more practical at this very moment," said Mr. Robichaud. "But then again, I will ask the staff to have a look at it and see what could be done in the short term."

As it stands, the department only monitors prescriptions the province covers for low-income seniors and people on income assistance, Susan Gamble, project manager of the prescription drug program in Fredericton, testified at the inquest.

The system records all prescriptions purchased through the person's drug card, she said. The government does not have the right to track prescriptions not put through on the cards, she said.

Every month, the system reviews data from the past three months, looking for "red flags," such as the person seeing three or more doctors, visiting three or more pharmacies, receiving nine or more prescriptions for the same drug, or more than 50 prescriptions in total, said Ms. Gamble.

It highlights about 25,000 cases per year, she said. Staff will then take a closer look at the cases. Dilaudid, an increasingly abused drug, is one of the first things they'll look for, she said.

If staff feels the cases warrant further investigation, they usually send letters to the pharmacies involved expressing concern. In many cases, there are legitimate explanations, such as the person being a palliative care patient, said Ms. Gamble.

If there is evidence of a problem, the government can restrict the person to one doctor and one pharmacy of their choice if they want to continue receiving benefits. But Medicare will still pay for the person to see another doctor and the government has no control over the person paying cash for prescriptions at other pharmacies, she said.

Mr. Beshara's file was not one that would have been flagged, said Ms. Gamble. Of the 13 prescriptions the government covered for him in 2000, all of them were from the same doctor and although he did go to a few different pharmacies, it wasn't within a three-month period. "His file is not one I would look into as far as restricting a client," she said.

The inquest heard from other witnesses that Mr. Beshara received at least eight other prescriptions that were not put through on his government card. Most of them were for Valium, which is relatively cheap compared to some other drugs, said Ms. Gamble.

Some people who know the system and don't want the government to know how many drugs they're getting will choose to pay cash for the cheaper drugs and only put the more expensive ones through on their cards, she said.

The government is always looking at improving processes, said Ms. Gamble. "With drug abuses province-wide, we continue to look to see what we can do to safeguard.

"There are a lot of thin lines" to balance, she said, citing the human rights of clients and the rights of doctors to prescribe.

If the province does decide to implement a drug monitoring program, several witnesses suggested using British Columbia's system, introduced in 1995, as a model.

PharmaNet, a partnership between the B.C. Ministry of Health and the College of Pharmacists of B.C., is a secure, real-time computer network that links all community pharmacies as well as many hospital pharmacies to a central database of information, which includes, among other things, patient medication histories and drug information.

Every time a prescription is dispensed, a medication profile for the patient is returned to the pharmacist for review. The profile includes all prescriptions dispensed at any pharmacy in the past 14 months, alerting the pharmacist to potential overprescribing or misuse of prescription drugs.

It also alerts the pharmacist if the dose prescribed or the duration of therapy is outside normal limits, provides warnings of potential harmful medication interactions, and provides, at the pharmacist's request, educational material for the patient.

It may also advise the pharmacist of any adverse reactions, allergies and clinical conditions recorded for the patient.

Response time for the system is usually about five seconds.

Statistics for the first three months of this year show that PharmaNet flagged:

372 cases of potential overuse/abuse

193 cases of suspected multiple-doctoring or polypharmacing

68 cases of falsified or altered prescriptions

more than 128,000 cases of potential drug interactions

The system has also been introduced in hospital emergency departments and, in a recent pilot, in doctors' offices.

PharmaNet operates behind a firewall that prevents unauthorized use. All users are required to sign confidentiality agreements before being granted access and must provide unique identifiers when logging into the system.

Patients can also ask a pharmacist to place a keyword on their patient profile, which further limits access. The patient simply reveals the keyword at the time of the purchase. In cases of emergency, if the patient is unable to provide the keyword, their doctor can contact the PharmaNet 24-hour help desk to request that the keyword be removed from the patient's profile.

The system cost about $20 million to set up and costs about $9 million annually to operate.

Although estimates of how much it would cost to implement a similar system in New Brunswick vary widely, most agree it would cost much less since it is a much smaller province.

The population of B.C. is about four million, up from about 3.8 million in 1995 when the system was established. By comparison, New Brunswick's population is only about 757,000.

New Brunswick also has far fewer pharmacies at 167, compared to B.C's 850.

HOUSE OKS CREATION OF DATABASE ON NARCOTICS IN SOUTHWEST VA.; [FINAL Edition]

KATRICE FRANKLIN THE VIRGINIAN-PILOT. **Virginian - Pilot**. Norfolk, Va.: Mar 8, 2002. pg. B.4

Abstract (Summary)

The House of Delegates voted 59-40 Thursday to begin devising a limited database that lists the names and addresses of Southwest Virginians who buy any of 16 narcotics, including codeine, morphine and opium.

The database, which would be kept confidential and controlled by the state Department of Health director, would take about 18 months to create. The intent is to stop drug abusers from taking prescriptions to several pharmacists to get them filled. To catch abusers, police must now visit pharmacists believed to have filled the addicts' prescriptions.

Graphic THE BILL The House of Delegates voted to begin devising a database of names and addresses of Southwest Virginians who buy any of 16 dangerous narcotics, including codeine, morphine and opium.

Swallowing strong pain medicine won't place most Virginians on a new controversial state database that tracks certain pharmacist- filled prescriptions.

But Southwest Virginians who take addictive narcotics - legally or illegally - will soon be a part of a prescription-monitoring program that some say is destined for the rest of the state.

The House of Delegates voted 59-40 Thursday to begin devising a limited database that lists the names and addresses of Southwest Virginians who buy any of 16 narcotics, including codeine, morphine and opium.

Supporters of the measure said the monitoring program would help the state crack down on drug abuse and save lives. Opponents warned that it could invade the privacy of legal drug users, including cancer patients.

An identical measure for a two-year test program has been approved by the Senate. The bill now goes to Gov. Mark R. Warner, who must decide whether to sign it into law.

The database, which would be kept confidential and controlled by the state Department of Health director, would take about 18 months to create. The intent is to stop drug abusers from taking prescriptions to several pharmacists to get them filled. To catch abusers, police must now visit pharmacists believed to have filled the addicts' prescriptions.

Access to the database would be restricted to state police actively investigating a suspected abuser. Anyone publicly releasing the confidential material would be subject to a maximum $2,500 fine and a year in jail.

Sponsors of the measure originally sought to make the database statewide and monitor a wider variety of drugs, including some cough syrups. But several lawmakers said the program infringed on personal privacy.

Del. S. Chris Jones, R-Suffolk, helped revise the bill. Jones, a pharmacist, admitted the problem isn't limited to Southwest Virginia.

During a lengthy debate on the bill, SB425, supporters said the database is the state's best attempt at stopping the escalating abuse of OxyContin. The drug is a prescribed pain killer that some people crush and inject to get high.

The addictions have resulted in more than 100 deaths nationwide, about half in Virginia and many in the southwest region which borders Kentucky and West Virginia. Both states have set up similar databases to stop the addictions.

Opponents said the program smacked of "Big Brother."

"It will inevitably have a chilling effect on doctors' willingness to prescribe pain medications," said Del. Kristen J. Amundson, D- Fairfax.

Amundson's father died last month of cancer. He took OxyContin.

"This is where the erosion of freedom begins ladies and gentlemen," said Del. Ward L. Armstrong, D-Henry.

Reach Katrice Franklin at (804) 697-1563 or kfrankli(AT)pilotonline.com

Registry may reduce illegal use of drug

THERESE SMITH COX. **Charleston Daily Mail**. Charleston, W.V.: Apr 19, 2001. pg. 6.C

Health and law enforcement officials hope the illicit use of the prescription painkiller OxyContin decreases under a new law awaiting the governor's signature. Legislators agreed to require the state Health Care Authority to create a central repository for information on certain drugs, including the practitioners who prescribed them, the pharmacies that filled the orders and the patients who received them.

The measure modifies the controlled substances monitoring act by targeting Schedule II, III and IV drugs selected by the Health Care Authority.

While Schedule I drugs are highly abused but have no accepted medical use, Schedule II drugs are those prescriptions with high abuse potential, such as oxycodone, amphetamines and morphine. Schedule III have less abuse potential and include acetaminophen with some quantities of narcotics. And Schedule IV drugs, such as benzodiazepines, carry even less abuse potential.

Sallie Hunt, the authority's chief policy officer, said the data will be confidential but will be available to the State Police and authorized state licensing boards, such as medicine, osteopathic medicine and pharmacy.

"It is in reaction to OxyContin problems and the need for the state to get its arms around pharmacy costs in general," Hunt said.

Sgt. Michael Corsaro, spokesman for the State Police, said the measure is another weapon in officers' arsenal against illegal use of narcotic substances.

"The State Police could use this as an excellent tool in the fight against certain narcotic substances," Corsaro said.

While Steve Neddo of the Metro Drug Unit said the registry could be a big help in tracking the illicit use of OxyContin and other addictive prescription drugs, he believes his office also should have access to the data bank.

OxyContin, a powerful drug often a godsend to those with advanced cancer pain, cost the state Medicaid program nearly $4 million last year and also was the most expensive drug group for the state Workers' Compensation Division during the last quarter of 2000.

Reports abound of the illicit use of the addictive narcotic by patients who shop for doctors who will prescribe it and pharmacies that will fill it. Others sell the prescription on the street at $1 a milligram.

Though Medicaid and Workers' Compensation can track OxyContin sales through reimbursement systems, they can't record data when people pay cash for the drug.

But the new law would require all legitimate sales of OxyContin and other targeted drugs to be recorded in a data bank.

Here's how it will work, said William Douglas, executive director and general counsel for the state Board of Pharmacy:

Once the targeted drugs are selected, every prescription filled will be transmitted electronically from the point of sale to the authority. Or, the information will go on a disk and be submitted monthly. The information will be organized by patient, doctor or drug, Douglas said.

"This is the only way to accurately know who is getting drugs from what doctors and pharmacies," Douglas said.

The bill also gives legal immunity to pharmacists for refusing to fill certain prescriptions.

West Virginia lawmakers implemented a similar law in 1996 but did not fund it adequately. After 18 months, it fizzled.

The Health Care Authority asked for $332,464 to implement the law this time and $80,282 a year thereafter, Hunt said. Legislators this week will decide if it's worth it.

Now 17 other states have similar laws, Douglas said.

"This could have great implications in the state in getting a handle on controlled substance abuse going on," he said. "We get anecdotal stories but what is true abuse? This is the only way to have specific data."

Therese Smith Cox can be reached at 348-4874 or by e-mail at therese@dailymail.com.

B. EBSCOhost

(((sensitive or monitored or controlled or regulated or addictive or illegal or "habit forming" or narcotizing) N3 (drug? or pharmaceutical? or pharmaeceutical? or substance? or medication or medicine?)) or narcotic? or opioid? or opiate?) AND (prescription? or prescribe? or prescribing) AND (track or monitor* or control* or restrict* or surveil* or manag* or regulat* or enforc* or inhibit* or limit* or restrain* or constrain* or prohibit* or supervis* or checking) AND (abuse? or abuser? or abusive* or abusing or misuse or misused or misusing or unscrupulous* or misprescribing) AND ((central or exclusive or main or master or primary or base or homebase or centrali?ed or controlling or solo or restricted or mainframe) N3 (database or databases or repositor*)) AND ((central or exclusive or main or master or primary or base or homebase or centrali?ed or controlling or solo or restricted) N3 (pharmacy or pharmacies or facility or facilities or druggist? or chemist? or location? or hospital? or apothecar*))*

Note: Your initial search query did not yield any results.

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L12	109	("4674652" | "4695954" | "4766542" | "4847764" | "4860899" | "4991877" | "5065315" | "5072383" | "5084828" | "5208762" | "5292029" | "5347453" | "5347477" | "5390238" | "5502944" | "5528021").PN. OR ("5737539").URPN.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/12/16 18:13
L14	4121	((705/3) or (600/300)).CCLS.	US-PGPUB	OR	OFF	2009/12/16 18:17
L15	6	((data adj1 base or database or repository or databank or data adj1 bank or storage) AND (prescription or drug or medication or pharmaceutical or medicine) AND (request) AND (patient) AND (exclusive or sole or single or main or one or specialty) AND (pharmacy) AND (abuse or misuse)).CLM.	US-PGPUB	OR	ON	2009/12/16 18:26

S2	10	(prescription or medication or pharmaceutical or medicine or drug) same (abus$ or misus $) same (doctor or prescriber or nurse or physician or professional) same (patient) same (database or data adj1 base or databank or data adj1 bank or repository) same (single or exclusive or central)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/08 15:20
S3	39	(prescription or medication or pharmaceutical or medicine or drug) same (abus$ or misus $) same (doctor or prescriber or nurse or physician or professional) same (patient) same (database or data adj1 base or databank or data adj1 bank or repository)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/08 15:21
S4	286	(prescription or medication or pharmaceutical or medicine or drug) with (abus$ or misus $) with (doctor or prescriber or nurse or physician or professional)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/08 15:24
S5	6	(prescription or medication or pharmaceutical or medicine or drug) with (abus$ or misus $) with (doctor or prescriber or nurse or physician or professional) with credential	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/08 15:24

S10	97	specialty same distribut$ same (drug or prescription or pharmaceutical or substance)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/09 16:42
S11	26	specialty same distribut$ same (drug or prescription or pharmaceutical or substance) same pharmacy	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/09 16:42
S13	17	specialty same distribut$ same (drug or prescription or pharmaceutical or substance) same (exclusive or single or sole)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/09 16:43
S14	4	specialty same distribut$ same FDA	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/09 16:43
S15	9	(specialty or exclusive) same distribut$ same FDA	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2009/12/09 16:43

EAST Search History (Interference)

<This search history is empty>

12/16/2009 6:28:59 PM
C:\Documents and Settings\lnajarian2\My Documents\EAST\Workspaces\10322348.wsp

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 5446

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/322,348	12/17/2002	436	3686	101.031US1

APPLICANTS

Dayton T. Reardan, Excelsior, MN;
Patti A. Eneel, Eagan, MN;
Bob Gagne, St. Paul, MN;

**** CONTINUING DATA **************************

**** FOREIGN APPLICATIONS **************************

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **** ** SMALL ENTITY **
03/21/2003

Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged /LENA NAJARIAN/ Examiner's Signature	☐ Met after Allowance LN Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
		MN	16	25	4

ADDRESS

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402
UNITED STATES

TITLE

Sensitive drug distribution system and method

FILING FEE RECEIVED		
767	FEES: Authority has been given in Paper No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

BIB (Rev. 05/07).

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	10322348	REARDAN ET AL.
	Examiner	Art Unit
	LENA NAJARIAN	3686

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	12/16/2009								
	1	-								
	2	-								
	3	-								
	4	-								
	5	-								
	6	-								
	7	-								
	8	-								
	9	-								
	10	-								
	11	-								
	12	-								
	13	-								
	14	-								
	15	-								
	16	-								
	17	-								
	18	-								
	19	-								
	20	-								
	21	-								
	22	-								
	23	-								
	24	-								
	25	-								
	26	-								
	27	-								
	28	-								
	29	-								
	30	-								
	31	-								
1	32	=								
2	33	=								
3	34	=								
4	35	=								
5	36	=								

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	10322348	REARDAN ET AL.
	Examiner	Art Unit
	LENA NAJARIAN	3686

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	12/16/2009								
6	37	=								
7	38	=								
8	39	=								
9	40	=								
10	41	=								
11	42	=								

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	10322348	REARDAN ET AL.
	Examiner	Art Unit
	LENA NAJARIAN	3686

SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
East (see attached printout) USPAT;US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	12/8/09	LN
East (see attached printout) USPAT;US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	12/9/09	LN
forward/backward search	12/16/09	LN
considered 705 template EIC search results	12/15/09	LN

INTERFERENCE SEARCH			
Class	Subclass	Date	Examiner
705	3	12/16/09	LN
600	300	12/16/09	LN
	PGPUB text search (see interference search printout)	12/16/09	LN

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	10322348	REARDAN ET AL.
	Examiner	**Art Unit**
	LENA NAJARIAN	3686

ORIGINAL		INTERNATIONAL CLASSIFICATION	
CLASS	SUBCLASS	CLAIMED	NON-CLAIMED
705	2	G 0 6 Q 10 / 00 (2006.0)	

CROSS REFERENCE(S)

CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
705	3				
600	300				

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1		17	2	33										
	2		18	3	34										
	3		19	4	35										
	4		20	5	36										
	5		21	6	37										
	6		22	7	38										
	7		23	8	39										
	8		24	9	40										
	9		25	10	41										
	10		26	11	42										
	11		27												
	12		28												
	13		29												
	14		30												
	15		31												
	16	1	32												

/LENA NAJARIAN/ Examiner.Art Unit 3686	12/16/09	**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	11	
/Gerald J. O'Connor/ SPE, GAU 3686	12/18/2009	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	2C

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23186 7590 12/31/2009

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

LeShere Wolfe	(Depositor's name)
/LeShere Wolfe/	(Signature)
January 6, 2010	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/322,348	12/17/2002	Dayton T. Reardan	101.031US1	5446

TITLE OF INVENTION: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	$755	$300	$0	$1055	03/31/2010

EXAMINER	ART UNIT	CLASS-SUBCLASS
NAJARIAN, LENA	3686	705-002000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ☒ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Schwegman, Lundberg
2 & Woessner, P.A.
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: JPI Commercial, LLC.

(B) RESIDENCE: (CITY and STATE OR COUNTRY): Palo Alto, California

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:
- ☒ Issue Fee
- ☒ Publication Fee (No small entity discount permitted)
- ☐ Advance Order - # of Copies

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
- ☐ A check is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 19-0743 (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
- ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature: /David D'Zurilla/ Date: January 6, 2010

Typed or printed name: David D'Zurilla Registration No.: 36,776

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Dayton T. Reardan et al.	Examiner:	Lena Najarian
Serial No.:	10/322,348	Group Art Unit:	3686
Filed:	December 17, 2002	Docket No.:	101.031US1
Customer No.:	21186	Confirmation No.:	5446
Title:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD		

COMMUNICATION RE: FEE ADDRESS

Mail Stop Issue Fee
Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

In response to the Notice of Allowance and Issue Fee Due, please record the Fee Address under the provisions of 37 CFR 1.363 as the following:

Customer Number 21186

Please direct any inquiries to the undersigned attorney at (612) 371-2140.

Respectfully submitted,

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2140

Date January 6, 2010 By /David D'Zurilla/

David D'Zurilla
Reg. No. 36,776

DDZ:CMG:lrw

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of January, 2010.

LeShere Wolfe
Name

/LeShere Wolfe/
Signature

Electronic Patent Application Fee Transmittal

Application Number:	10322348
Filing Date:	17-Dec-2002
Title of Invention:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD
First Named Inventor/Applicant Name:	Dayton T. Reardan
Filer:	Karen L. Himmel/LeShere Wolfe
Attorney Docket Number:	101.031US1

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Publ. Fee- early, voluntary, or normal	1504	1	300	300
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl issue fee	2501	1	755	755

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	1055

Electronic Acknowledgement Receipt	
EFS ID:	6757671
Application Number:	10322348
International Application Number:	
Confirmation Number:	5446
Title of Invention:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD
First Named Inventor/Applicant Name:	Dayton T. Reardan
Customer Number:	21186
Filer:	Karen L. Himmel/LeShere Wolfe
Filer Authorized By:	Karen L. Himmel
Attorney Docket Number:	101.031US1
Receipt Date:	06-JAN-2010
Filing Date:	17-DEC-2002
Time Stamp:	12:43:34
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$1055
RAM confirmation Number	7625
Deposit Account	190743
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		101031US1ISSUEXMIT.pdf	404199 f3fe1ec2124e710154d055d8e6ea1e23715e9960	yes	3

Multipart Description/PDF files in .zip description

Document Description	Start	End
Miscellaneous Incoming Letter	1	1
Issue Fee Payment (PTO-85B)	2	2
Change of Address	3	3

Warnings:

Information:

2	Fee Worksheet (PTO-875)	fee-info.pdf	31811 173b20be1135a947c5a5e4b4f653c95572a62e5f	no	2

Warnings:

Information:

Total Files Size (in bytes):	436010

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dayton T. Reardan et al.

Title: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD

Docket No.:	101.031US1	Serial No.:	10/322,348
Filed:	December 17, 2002	Due Date:	March 31, 2010
Examiner:	Lena Najarian	Group Art Unit:	3686
Customer No.:	21186	Confirmation No.:	5446

Notice of Allowance Date: December 31, 2009

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following:

X Authorization to charge Deposit 19-0743 in the amount of $755.00 to cover the Small Entity Issue Fee Payment.
X Authorization to charge Deposit 19-0743 in the amount of $300.00 to cover the Publication Fee Payment.
X Issue Fee Transmittal (Form PTOL-85).
X Communication Re: Fee Address (1 page).

Please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG & WOESSNER, P.A. By /David D'Zurilla/
Customer No.: 21186 David D'Zurilla
DDZ:CMG:lrw Reg. No. 36,776

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of January, 2010.

LeShere Wolfe
Name

/LeShere Wolfe/
Signature

IN THE SPECIFICATION

Please amend the paragraph on page 6, starting at line ~~17~~ 15 as follows:

If the information is complete at 212, the MD is contacted at 220 to verify receipt and accuracy of the patient's Rx. This contact is recorded in CHIPS. The intake and reimbursement specialist then sends a consent form and a cover letter to the patient at 224. The insurance provider is contacted at 226 to verify coverage and benefits. At 228, a determination is made regarding coverage for the drug. If it is not available, it is determined at 230 whether the patient is willing and able to pay. If not, a process 232 is performed for handling patients who are uninsured or underinsured. In one embodiment, the process is referred to as a NORD process.

Please amend the paragraph on page 6, starting at line ~~25~~ 23 as follows:

If the patient is willing and able to pay at 230, the patient is informed of the cost of the product and is given payment options at 234. At 236, once payment is received, the intake reimbursement specialist submits a coverage approval form with the enrollment form to the pharmacy team as notification to process the patient's prescription. If coverage is approved at 228, the intake reimbursement specialist also submits the coverage ~~coveral~~ approval form at 238 with the enrollment form to the pharmacy team as notification to process the patient's prescription. Processing of the prescription is described below.

Please amend the paragraph on page 7, starting at line ~~18~~ 16 as follows:

If any disciplinary actions are identified, as referenced at block 278, management of the pharmacy is notified and either approves processing of the prescription with continued monitoring of the physician, or processing of the prescription is not performed, and the physician is noted in the database as unapproved at 284. The MD is contacted by a pharmacist at 286, and informed that the patient's Rx cannot be processed. The enrollment form is then mailed back to the physician with a cover letter reiterating that the prescription cannot be processed at 288. The patient is also sent a letter at 290 indicating that the prescription cannot be processed and the patient is instructed to contact their physician.

Please amend the paragraph on page 8, starting at line ~~12~~ 9 as follows:

At 254, the pharmacist enters the prescription order in the database, creating an order number. The pharmacist then verifies at 256 the prescription and attaches a verification label to the hard copy prescription. At 258, a pick ticket is generated for the order and the order is forwarded to the pharmacy for fulfillment. The shipment is confirmed in the database at 260, the original Rx is filed with the pharmacy Rx's in numerical order at 262, and the order is shipped by USPS Express Mail 264. Use of the US mail invokes certain criminal penalties for unauthorized diversion. Optionally, other mail services may be used. Potential changes in the law may also bring criminal penalties into play. Following shipment, the patient is called by the central pharmacy to confirm that the prescription was received.

Please amend the paragraph on page 8, starting at line ~~29~~ 20 as follows:

A refill request process begins at ~~302~~ 402 in FIG.s 4A and 4B. There are two different paths for refills. A first path beginning at 404 involves generating a report from the central database of patients with a predetermined number of days or product remaining. A second path beginning at 406 is followed when a patient calls to request an early refill.

Please amend the paragraph on page 9, starting at line 12 as follows:

The second path, beginning at 406 results in a note code being entered into the database on a patient screen indicating an early refill request at 432. At 434, a sensitive drug problem identification and management risk diversion report may be completed, documented and distributed. The pharmacist evaluates the patient's compliance with therapy or possible product diversion, misuse or over-use at 436. In one embodiment, cash payers are also identified. The pharmacist then contacts the prescribing physician to alert them of the situation and confirm if the physician approves of the early refill at 438. If the physician does not approve as indicated at 440, the patient must wait until the next scheduled refill date to receive additional product as indicated at 442, and the process ends at 444.

Please amend the paragraph on page 12, starting at line ~~8~~ 1 as follows:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dayton T. Reardan et al.

Title: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD

Docket No.:	101.031US1	Serial No.:	10/322,348
Filed:	December 17, 2002	Due Date:	N/A
Examiner:	Lena Najarian	Group Art Unit:	3686
Customer No.:	21186	Confirmation No.:	5446

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the attached:

X Communication Re: Incorrect Filing Receipt (1 pg..)
X Copy of Filing Receipt (3 pgs.)
X Copy of Executed Combined Declaration and Power of Attorney(4 pgs.)

It is believed that no additional fee is required. However, if necessary, please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

Schwegman, Lundberg & Woessner, P.A.
Customer No.: 21186
DDZ:CMG:lrw

By /David D'Zurilla/
David D'Zurilla
Reg. No. 36,776

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21st day of January, 2010.

LeShere Wolfe
Name

/LeShere Wolfe/
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Dayton T. Reardan et al.	Examiner: Lena Najarian	
Serial No.:	10/322,348	Group Art Unit: 3686	
Filed:	December 17, 2002	Docket: 101.031US1	
Customer No.:	21186	Confirmation No.: 5446	
Title:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD		

COMMUNICATION RE: INCORRECT FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants hereby request correction of the Filing Receipt with respect to the above-identified patent application. In the Filing Receipt mailed August 13, 2003 (copy enclosed), The Full Name of Joint Inventor number 2 should read **Patti A. Engel** this is evidenced by a copy of the Combined Declaration and Power of Attorney as filed May 21, 2003(copy attached).

Applicants respectfully request that the above-identified printing error(s) be corrected and that a Corrected Filing Receipt be sent to Applicants' representatives at the address given below.

Respectfully submitted,

Schwegman, Lundberg & Woessner, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2140

Date January 21, 2010 By /David D'Zurilla/

David D'Zurilla
Reg. No. 36,776

DDZ:CMG:lrw

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21st day of January, 2010.

LeShere Wolfe
Name

/LeShere Wolfe/
Signature

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/322,348	12/17/2002	1743	527	101.031US1	16	25	4

CONFIRMATION NO. 5446

21186
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

UPDATED FILING RECEIPT

OC000000010690004

Date Mailed: 08/13/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Dayton T. Reardan, Excelsior, MN;
Patti A. Eneel, Eagan, MN;
Bob Gagne, St. Paul, MN;

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted: 03/21/2003

Projected Publication Date: 06/17/2004

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Sensitive drug distribution system and method

Preliminary Class

PORTFOLIO I.P.
AUG 18 2003
RECEIVED

FRCT-3

436

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SCHWEGMAN ■ LUNDBERG ■ WOESSNER ■ KLUTH

United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: **SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD**.

The specification of which was filed on December 17, 2002 as application serial no. 10/322,348.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. § 1.56 (attached hereto). I also acknowledge my duty to disclose all information known to be material to patentability which became available between a filing date of a prior application and the national or PCT international filing date in the event this is a Continuation-In-Part application in accordance with 37 C.F.R. § 1.63(e).

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

No such claim for priority is being made at this time.

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

No such claim for priority is being made at this time.

I hereby claim the benefit under 35 U.S.C. § 120 or 365(c) of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

No such claim for priority is being made at this time.

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Anglin, J. M	Reg. No. 24,916	Harris, Robert J	Reg. No. 37,346	Nielsen, Walter W	Reg. No. 25,539
Arora, Suneel	Reg. No. 42,267	Jackson Huebsch, Katharine A	Reg. No. 47,670	Padys, Danny J	Reg. No. 35,635
Beekman, Marvin L	Reg. No. 38,377	Jurkovich, Patti J	Reg. No. 44,813	Parker, J. K	Reg. No. 33,024
Bianchi, Timothy E	Reg. No. 39,610	Kalis, Janal M	Reg. No. 37,650	Peacock, Gregg A	Reg. No. 45,001
Billion, Richard E	Reg. No. 32,836	Klima-Silberg, Catherine I	Reg. No. 40,052	Perdok, Monique M	Reg. No. 42,989
Black, David W	Reg. No. 42,331	Kluth, Daniel J	Reg. No. 32,146	Peret, Andrew R	Reg. No. 41,246
Brennan, Thomas F	Reg. No. 35,075	Lacy, Rodney L	Reg. No. 41,136	Peterson, David C	Reg. No. 47,857
Chadwick, Robin A	Reg. No. 36,477	Lemaire, Charles A	Reg. No. 36,198	Prout, William F	Reg. No. 33,995
Clark, Barbara J	Reg. No. 38,107	Lundberg, Steven W	Reg. No. 30,568	Puckett, Ph. D., Craig L	Reg. No. 43,023
Clise, Timothy B	Reg. No. 40,957	Maki, Peter C	Reg. No. 42,832	Schumm, Sherry W	Reg. No. 39,422
Cochran, David R	Reg. No. 46,632	Malen, Peter L	Reg. No. 44,894	Schwegman, Micheal L	Reg. No. 25,816
Dahl, John M	Reg. No. 44,639	Mates, Robert E	Reg. No. 35,271	Speier, Gary J	Reg. No. 45,458
Drake, Eduardo E	Reg. No. 40,594	McCrackin, Ann M	Reg. No. 42,858	Steffey, Charles E	Reg. No. 25,179
Embretson, Janet E	Reg. No. 39,665	McGough, Kevin J	Reg. No. 31,279	Stordal, Leif T	Reg. No. 46,251
Forrest, Bradley A	Reg. No. 30,837	McTavish, Hugh E	Reg. No. 48,341	Terry, Kathleen R	Reg. No. 31,884
Gorrie, Gregory J	Reg. No. 36,530	Mehrle, Joseph P	Reg. No. 45,535	Tong, Viet V	Reg. No. 45,416
Gortych, Joseph E	Reg. No. 41,791	Muller, Mark V	Reg. No. 37,509	Viksnins, Ann S	Reg. No. 37,748
Greaves, John N	Reg. No. 40,362	Nama, Prakash	Reg. No. 44,255	Woessner, Warren D	Reg. No. 30,440
Haack, John L	Reg. No. 36,154	Nelson, A. J	Reg. No. 28,650		

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Schwegman, Lundberg, Woessner & Kluth, P.A. to the contrary.

Please direct all correspondence in this case to **Schwegman, Lundberg, Woessner & Kluth, P.A.** at the address indicated below:

P.O. Box 2938, Minneapolis, MN 55402
Telephone No. (612)373-6900

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of joint inventor number 1 : **Dayton T. Reardan Ph.D.**
Citizenship: **United States of America** Residence: **Excelsior, MN**
Post Office Address: 22345 Bracketts Road
Excelsior, MN 55331

Signature: Dayton T. Reardan Date: April 3, 2003
Dayton T. Reardan Ph.D.

Full Name of joint inventor number 2 : **Patti ~~Engle~~ A. ENGEL**
Citizenship: **United States of America** Residence: **Eagan, MN**
Post Office Address: 852 Basswood Lane
Eagan, MN

Signature: Patti A. Engel Date: May 13, 2003
Patti ~~Engle~~
PATTI A. ENGEL

X Additional inventors are being named on separately numbered sheets, attached hereto.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of joint inventor number 3 : **Bob Gagne**
Citizenship: **United States of America** Residence: **St. Paul, MN**
Post Office Address: 202 So. Wheeler Street
St. Paul, MN 55015

Signature: Bob Gagne Date: 1 May 2003
Bob Gagne

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application:

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

Electronic Acknowledgement Receipt	
EFS ID:	6853196
Application Number:	10322348
International Application Number:	
Confirmation Number:	5446
Title of Invention:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD
First Named Inventor/Applicant Name:	Dayton T. Reardan
Customer Number:	21186
Filer:	Karen L. Himmel/LeShere Wolfe
Filer Authorized By:	Karen L. Himmel
Attorney Docket Number:	101.031US1
Receipt Date:	21-JAN-2010
Filing Date:	17-DEC-2002
Time Stamp:	13:24:57
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		101031US1XMITFRCT.pdf	483112 b701123ebfa35d0c43d6fb57ef1eb73b7d1e0f62	yes	8

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Miscellaneous Incoming Letter	1	1
	Request for Corrected Filing Receipt	2	2
	Miscellaneous Incoming Letter	3	4
	Oath or Declaration filed	5	8
Warnings:			
Information:			
	Total Files Size (in bytes):	483112	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/322,348	02/23/2010	7668730	101.031US1	5446

21186 7590 02/03/2010

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 446 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Dayton T. Reardan, Excelsior, MN;
Patti A. Eneel, Eagan, MN;
Bob Gagne, St. Paul, MN;

MODIFIED PTO/SB/131 (01-10)
Approved for use through 02/28/2011. OMB 0651-0020
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

REQUEST FOR RECALCULATION OF PATENT TERM ADJUSTMENT IN VIEW OF *WYETH**

Attorney Docket Number: 101.031US1	Patent Number: 7,668,730
Filing date (or 371(b) or (f) Date): December 17, 2002	Issue Date: February 23, 2010
First Named Inventor: Dayton T. Reardan et al.	
Title: SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD	

PATENTEE HEREBY REQUESTS RECALCULATION OF THE PATENT TERM ADJUSTMENT (PTA) UNDER 35 USC 154(b) INDICATED ON THE ABOVE-IDENTIFIED PATENT. THE PATENTEE'S SOLE BASIS FOR REQUESTING THE RECALCULATION IS THE USPTO'S PRE-WYETH INTERPRETATION OF 35 U.S.C. 154(b)(2)(A).

Note: This form is only for requesting a recalculation of PTA for patents issued before March 2, 2010, if the sole basis for requesting the recalculation is the USPTO's pre-*Wyeth* interpretation of 35 U.S.C. 154(b)(2)(A). See Instruction Sheet on page 2 for more information.

Patentees are reminded that to preserve the right to review in the United States District Court for the District of Columbia of the USPTO's patent term adjustment determination, a patentee must ensure that he or she also takes the steps required under 35 U.S.C. 154(b)(3) and (b)(4) and 37 CFR 1.705 in a timely manner.

**Wyeth v. Kappos*, No. 2009-1120 (Fed. Cir., Jan. 7, 2010).

Signature / Monique M. Perdok Shonka /	Date Feb. 23, 2010
Name: Monique M. Perdok Shonka	Registration Number: 42,989

Note: *Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature. If necessary, submit multiple forms for more than one signature, see below**.

☒ *Total of 1 forms are submitted.

Electronic Acknowledgement Receipt

EFS ID:	7065280
Application Number:	10322348
International Application Number:	
Confirmation Number:	5446
Title of Invention:	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD
First Named Inventor/Applicant Name:	Dayton T. Reardan
Customer Number:	21186
Filer:	Barbara Jean Clark/Peter Rebuffoni
Filer Authorized By:	Barbara Jean Clark
Attorney Docket Number:	101.031US1
Receipt Date:	23-FEB-2010
Filing Date:	17-DEC-2002
Time Stamp:	11:53:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for PTA recalculation in view of Wyeth	101_031US1_PTA.pdf	57837 5cf8f9b917fe17384f05dfa7300530cb35c08 1ba	no	1

Warnings:	
Information:	

Total Files Size (in bytes):	57837

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

Mail Date: 04/20/2010

Applicant	: Dayton T. Reardan	: DECISION ON REQUEST FOR
Patent Number	: 7668730	: RECALCULATION of PATENT
Issue Date	: 02/23/2010	: TERM ADJUSTMENT IN VIEW
Appliction No	: 10/322,348	: OF WYETH AND NOTICE OF INTENT TO
Filed	: 12/17/2002	: ISSUE CERTIFICATE OF CORRECTION
		:

The Request for Recalculation is **GRANTED** to the extent indicated.

The patent term adjustment has been determined to be **547** days. The USPTO will *sua sponte* issue a certificate of correction reflecting the amount of PTA days determined by the recalculation.

Prior to the issuance of the certificate of correction, the USPTO will afford patentee an opportunity to be heard and request reconsideration. Accordingly, patentee has **one month or thirty (30) days**, whichever is longer, to file a request for reconsideration of this patent term adjustment calculation. See 35 U.S.C. 154(b)(3)(B)(ii) and 37 CFR 1.322(a)(4). No extensions of time will be granted under 37 CFR 1.136.

Patentee should use document code PET.OP if electronically filing a request for reconsideration of this patent term adjustment calculation. The patentee must also include the information required by 37 CFR 1.705(b)(2) and the fee required by 37 CFR 1.18(e). If patentee does not file a timely request for reconsideration of this patent term adjustment calculation including the information required by 37 CFR 1.705(b)(2) and the fee required by 37 CFR 1.18(e), the USPTO will issue a certificate of correction reflecting the PTA determination noted above.

Patentee should be aware that in order to preserve the right to review in the United States District Court for the District of Columbia of the USPTO patent term adjustment determination, patentee must ensure that he or she also take the steps required under 35 U.S.C. 154(b)(4)(A) in a timely manner. Nothing in the request for recalculation should be construed as providing an alternative time frame for commencing a civil action under 35 U.S.C. 154(b)(4)(A).

Any questions concerning this decision should be directed to the Office of Patent Legal Administration at 571-272-7702.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,668,730 B2
APPLICATION NO. : 10/322348
DATED : February 23, 2010
INVENTOR(S) : Reardan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

The first or sole Notice should read --

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 547 days.

Signed and Sealed this

Seventh Day of December, 2010



David J. Kappos
Director of the United States Patent and Trademark Office